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ABSTRACT 
Introduction 
Given the increasing prevalence of non-typhoidal salmonella in humans, especially as an 
opportunistic illness associated with HIV, enhanced surveillance for non-typhoidal 
salmonella (NTS), including screening for antibiotic resistance, is conducted annually in 
South Africa. We aimed to determine whether there is an association between 
trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis and multi-drug resistant NTS 
infection, to establish whether various factors modify the relationship between TMP-SMX 
resistance and invasive NTS infection, to examine whether these associations vary by 
province, and to quantify the resistance rates of NTS to a range of antibiotics. 
Methods 
This study was a secondary analysis of enhanced surveillance data on NTS collected 
between 2003 and 2005. We used descriptive methods to assess the prevalence of NTS by 
year, province and serotype, and to determine the prevalence of four MDR patterns. 
Univariate and multivariate regression models were used to investigate the relationships 
between TMP-SMX prophylaxis and MDR NTS. Univariate logistic regression was used 
to assess the relationship between invasive NTS and TMP-SMX resistance. 
Results 
TMP-SMX prophylaxis is associated with the ACKSSuT pattern (OR 1.91, 95% CI 1.14 – 
3.19, p=0.0080) and the AKSSuT MDR pattern (OR 2.00, 95% CI 1.26 – 3.15, p=0.0015). 
Being on TMP-SMX prophylaxis is associated with an increased odds of having at least 
one of the four MDR patterns investigated (OR 1.43, 95% CI 1.00 – 2.04, p=0.0388). We 
also found high rates of resistance to all antibiotics tested except for ciprofloxacin and 
imipenem. The highest resistance rate was observed for sulfamethoxazole (>75.85%). S. 
enterica Isangi isolates showed the highest levels of resistance, with 94.43% having at 
least one MDR pattern. Other factors significantly associated with MDR NTS were ESBL 
production, prior treatment with antibiotics, HIV status and resistance to TMP-SMX. 
Discussion and conclusions 
Isolates from patients on TMP-SMX prophylaxis were associated with an increased odds 
of having the ACKSSuT and AKSSuT MDR patterns, not taking into account other 
explanatory factors. These associations did not remain significant when possible 
 v
confounders were taken into account. Despite the threat of increased multi-drug resistance, 
TMP-SMX prophylaxis remains important in certain clinical settings. 
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1.0 INTRODUCTION 
This section presents a brief overview of Salmonella spp, in particular non-typhoidal 
salmonellae (NTS) and antibiotic resistance. The section ends with a review of pertinent 
and recent literature and a statement of the aim and objectives of the research undertaken. 
1.1 Background 
1.1.1 Salmonellae 
Salmonellae are Gram-negative, rod-shaped bacteria. There are more than 1800 serotypes 
(variants) of salmonellae. NTS serotypes (those which do not cause typhoid fever, i.e. all 
except S enterica, serotypes Typhi and Paratyphi) are primarily animal pathogens and their 
increasing prevalence in humans is therefore of interest (EMEA, 1999; Gianella, 2005). 
These organisms are food- or water-borne and transmission is usually faecal-oral, brought 
about by poor hygiene, inferior sanitation and poor-quality water supply. Whilst 
salmonellae are ubiquitous, they pose a particular public health problem in developing 
countries.   
NTS infections are increasingly reported in patients with Acquired Immune Deficiency 
Syndrome (AIDS), who often present with recurrent NTS infections, bacteraemia and 
septicaemia (Arthur et al, 2001; Hohmann, 2001; Pasquali, 2004; Yen et al, 2007). 
HIV/AIDS is considered a risk factor for NTS infection as NTS was isolated from 35% of 
HIV-infected adults in a recent study (Hohmann, 2001). NTS may therefore be an 
opportunistic illness associated with AIDS. Other risk factors for salmonella infection 
include extremities of age, immune suppression, exposure to contaminated food and water 
(especially poultry and eggs), travel to other countries and contact with domestic / 
agricultural / wild animals (Hohmann, 2001; Doré et al, 2004; Pasquali, 2004).   
Salmonellae may be invasive or non-invasive – this refers to the ability of the bacteria to 
cross the intestinal epithelium and cause systemic disease (Gianella, 2005). As immune 
suppression is thought to be a contributory factor to the development of invasive 
salmonellosis and as HIV/AIDS and/or immune suppression is a known risk factor for 
salmonellosis itself, this disease is of particular interest in developing countries with high 
HIV prevalence rates (Gianella, 2005). 
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1.1.2 Antibiotic resistance 
Antibiotic resistance is not a new phenomenon brought about solely by antibiotic use; 
rather it has been in existence in some instances even before the development of 
antibiotics for therapeutic use. Drug resistance can therefore be attributed to a combination 
of two factors, namely the antibiotic, which exerts a selection pressure for the resistant 
organism, and the organism itself, which may be genetically predisposed to the resistance 
selected for by that antibiotic. Continual use of an antibiotic to which certain strains of 
bacteria are resistant leads to an amplification of those strains and a decreased growth of 
susceptible strains (Levy and Marshall, 2004). In this manner, the drug-resistant strains 
become the predominant ones.  
Organisms may be multi-drug-resistant, meaning that they are resistant to more than one 
antibiotic or more than one class of antibiotics  Single-drug resistance was noted quite 
early on in the use of antibiotics and multi-drug resistance in enteric bacteria was first 
noted in the 1950’s (Levy and Marshall, 2004). A common pattern of resistance has been 
identified in salmonellae: the classic penta-resistance pattern, abbreviated as ACSSuT 
(Glynn et al, 1998; Helms et al, 2005). Organisms exhibiting this resistance pattern are not 
susceptible to the antibiotics ampicillin, chloramphenicol, streptomycin, sulphonamides 
and tetracyclines. Further resistance patterns have been observed, namely AKSSuT (with 
kanamycin replacing chloramphenicol), ACKSSuT and ACSSuTNx (with nalidixic acid 
added to the classic penta-resistance pattern) (Helms et al, 2002; Rabatsky-Ehr et al, 
2004). 
The problem of resistance in salmonellae is exacerbated by the burgeoning HIV epidemic 
and its treatment regimens, including the use of trimethoprim-sulfamethoxazole (TMP-
SMX) to prevent opportunistic infections. Two major factors implicated in the 
development of antibiotic resistance in bacteria are the use of antibiotics and the presence 
(in the bacteria) of a resistance gene (EMEA, 1999). Over-prescribing of antibiotics, 
utilization at sub-therapeutic dosages and inappropriate selection of antibiotics for therapy 
have all been identified as factors associated with the development of antibiotic resistance 
(EMEA, 1999; School of Public and Community Health, Washington, 2000; Tambic and 
Andrasevic, 2002). While considerable progress has been made in understanding the 
biochemical / molecular mechanisms of antibiotic resistance, few studies have examined 
the factors associated with antibiotic resistance and quantified these associations.  
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1.2 Literature review 
1.2.1 Prevalence of Resistant NTS Internationally 
Numerous studies have acknowledged that antibiotic resistance is a burgeoning global 
public health problem. Levy and Marshall highlighted the increasing scope of drug 
resistance in organisms in terms of the drugs to which bacteria are becoming resistant, the 
organisms becoming resistant and the geographical distribution of antibiotic resistance 
(Levy and Marshall, 2004). They point out that resistance mechanisms are known to exist 
to all classes of antibiotics. 
Helms and others examined the prevalence of S. enterica Typhimurium DT104 infections 
as well as antimicrobial resistance in this organism (Helms et al, 2005). Their work was 
based on surveillance data from 29 countries collected between 1992 and 2001, and noted 
an increase in the prevalence of DT104 infections from 8.7% in 1992 to 33% in 2001. 
They also reported on the increase in the proportion of resistant DT104 isolates from 15% 
to 42% respectively. Helms et al also found a slight decrease in the prevalence of MDR 
DT104 isolates from 99% to 94% but an increase in resistance to quinolones and TMP 
over the study period.  
Vugia and co-workers  examined the population-based FoodNet dataset to assess the 
incidence, clinical outcome and predominant serotypes of invasive salmonellae infections 
for the period 1996 – 1999 (Vugia et al, 2004). They found an overall annual incidence of 
0.9 cases of invasive salmonellosis per 100 000 population. Vugia et al also found that 
74% of cases were caused by eight salmonellae serotypes including S. enterica 
Typhimurium and S. enterica Enteritidis. The authors acknowledged the limitations of the 
study including missed cases, lack of complete data on HIV and other underlying illnesses, 
and lack of representativeness / generalisability to the US population. The authors also 
acknowledge that there is little published work on invasive salmonellosis, despite its 
prevalence in children, the elderly and immune-compromised people (including HIV-
positive people) even given the severity of the condition. 
Glynn and others also analysed the data collected by the FoodNet surveillance programme. 
This case-control study aimed to assess risk factors for non-outbreak-related S. enterica 
Typhimurium DT104 in the United States (Glynn et al, 2004). Glynn et al found an overall 
incidence of 4.3 S. enterica Typhimurium DT104 cases per 100 000 people. They also 
found that a large proportion (69%) of MDR isolates were S. enterica Typhimurium 
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DT104, and that 88% of MDR isolates exhibiting a penta-resistance pattern were S. 
enterica Typhimurium DT104.  
A common finding in the study was that participants were likely to have been treated with 
an antibiotic (in particular one of the ACKSSuT antibiotics) to which the infecting strain 
of S. enterica Typhimurium was resistant, with an odds ratio (OR) of 2.86 (95%CI 1.3-
6.1) for a matched case-control study comparing all infected individuals with healthy 
controls, and 5.7 (95% CI 1.8-17.4) when participants infected with MDR NTS were 
compared with healthy controls (Glynn et al, 2004). This OR increased to 19.7 (3.7-105.7) 
when individuals infected with MDR NTS were compared with people infected with NTS 
susceptible to all antibiotics. The case-control study design used by Glynn et al was 
appropriate in order to achieve the authors’ goals. The authors claim that cases are similar 
to controls, having been chosen from the same population, but acknowledge the 
limitations of the study in terms of similarity of cases to those not included in the case-
control study, recall bias and generalisability to the entire US population. 
The Alliance for the Prudent Use of Antibiotics (APUA) reported that S. enterica 
Enteritidis and Dublin were less likely to be resistant than S. enterica Typhimurium 
isolates (APUA, 2003). 
Rabatsky-Ehr and co-workers (Rabatsky-Ehr et al, 2004) conducted a review of data 
collected by the National Antimicrobial Resistance Monitoring System (NARMS) to 
determine resistance patterns and describe the spread of S. enterica Typhimurium phage 
types in the US, between 1997 and 1998. They found that S. enterica Typhimurium 
constituted 25% of NTS isolates tested. These isolates were very resistant to 
sulfamethoxazole (58%), streptomycin (51%), tetracycline (48%) and chloramphenicol 
(35%). Fifty eight percent of S. enterica Typhimurium isolates were resistant to at least 
one drug, 54% to two or more drugs and 48% to five drugs. The MDR resistance patterns 
(i.e. to five or more drugs) were: 
 ACSSuT – 67% of isolates 
 ACKSSuT – 8% of isolates 
 AKSSuT – 20% of isolates 
ACSSuT phenotypes were more likely to be isolated from a sterile site (i.e. invasive) as 
compared to the other resistance phenotypes or pansusceptible strains (p<0.01). This study 
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was quite comprehensive, with a clear and appropriate study design, and provides a good 
picture of the descriptive epidemiology of S. enterica Typhimurium R-type ACSSuT, but 
does not examine co-resistance factors such as immune-compromise. The study is limited 
to the 14 states that participated, and it is therefore questionable how generalisable this is 
to all of the US. The authors acknowledge this limitation, but do not address the issues of 
sample bias and representativeness. 
1.2.2 Prevalence of Resistant NTS in South Africa / Africa 
There is a paucity of information on the prevalence of NTS in Southern Africa. However, 
the National Institute for Communicable Diseases (NICD) has been collecting data as part 
of a national antimicrobial resistance surveillance programme. Kruger and others found 
that 59% of isolates were invasive NTS producing a positive blood culture (Kruger et al, 
2004). Of the NTS isolates analysed for this period, 15.6% were expanded spectrum beta-
lactamase (ESBL) producers and also demonstrated multi-drug resistance to ampicillin, 
TMP-SMX, chloramphenicol and nalidixic acid. Resistance to the latter implies that these 
infections may not be ideally treated with floroquinolones. This study focussed on 
characterizing the molecular epidemiology of NTS in South Africa and did not identify 
risk factors for co-resistance.  
More recently, the NICD recorded 1874 NTS isolates for 2006, of which 52.2% were 
invasive (GERMSSA, 2006). They also found that 50% of 1751 isolates tested exhibited 
resistance to five or more antibiotics, while the prevalence of resistance to TMP-SMX was 
50.7%. The most common serotype amongst both invasive and non-invasive NTS was S. 
enterica Typhimurium (68%), followed by S. enterica Isangi (19%) and S. enterica 
Enteritidis (8%). During the same period, the NICD also found that the highest incidence 
rate of invasive NTS was in the <1year age group (NICD, 2006). However, there was no 
analysis of what may have been associated with the antimicrobial resistance pattern 
observed. 
Helms et al (2005) reported that S. enterica Typhimurium was cultured from 51.3% of 
NTS isolates submitted for phage typing in South Africa in 2000-2001, of which 11.2% 
were multidrug-resistant, while 74% of S. enterica Typhimurium isolates tested in 
Southern Africa were multidrug-resistant. As South African data was only submitted for 
one year, it was not possible to look at trends in prevalence of resistance over time. 
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Furthermore, this study was a survey of annual data and the role of co-resistance and other 
factors in the development of multidrug-resistance were not explored. 
Mwansa and others examined the prevalence and antimicrobial resistance patterns of 
intestinal bacteria in HIV-infected patients in Zambia. They found that the prevalence of 
NTS was (Mwansa et al, 2002): 
 5% in adults with persistent diarrhoea 
 20% in children with persistent diarrhoea 
 <1% in asymptomatic adults  
In addition, there appeared to be an overall decrease in sensitivity to antimicrobials during 
the period of the study, with only 22% of 158 NTS isolates susceptible to SMX. Based on 
the resistance patterns observed, Mwansa et al concluded that NTS would be best treated 
with expensive floroquinolones as opposed to more cost-effective antibiotics. 
Kariuki and others analysed the resistance profiles of 342 NTS isolates from adults 
admitted to hospitals in Nairobi, Kenya, between 1994 and 2003 (Kariuki et al, 2005). 
They reported that only 16% of isolates tested between 1994 and 1997 were susceptible to 
all eleven antibiotics, while 47.9% were resistant to at least three of the eleven antibiotics 
tested. They did not observe a significant difference in resistance by each of the serotypes 
identified during this study. Resistance to ciprofloxacin was not observed during the 
period this study was undertaken. Kariuki et al also documented an increase in the 
prevalence of resistance to several antibiotics, including ampicillin, streptomycin, TMP-
SMX and chloramphenicol. 
1.2.3 Prevalence of NTS in HIV-positive people 
HIV is known to increase the frequency and severity of salmonella infection as well as the 
development of resistance to antibiotics by suppression of natural host defences against 
salmonellosis (Gianella, 1996). NTS infections are increasingly reported in patients with 
Acquired Immune Deficiency Syndrome (AIDS), who often present with recurrent NTS 
infections, bacteraemia and septicaemia (Gianella, 1996). HIV/AIDS is considered a risk 
factor for NTS infection:  Keddy et al state that the NTS bacteraemia-specific mortality 
rate in HIV infection may be between 23 and 47% (Keddy et al, 2005). Also, NTS, 
considered an opportunistic illness associated with AIDS (especially recurrent bacteraemic 
NTS), was isolated from 35% of HIV-infected adults in a recent study (Doré et al, 2004). 
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Pegues and Miller reported that S. enterica Enteritidis bacteraemia affected HIV-positive 
individuals disproportionately (though less so recently, possibly because of the use of 
zidovudine which is known to act against S. enterica Enteritidis), a fully functioning 
immune system is required to effectively combat salmonellae (Pegues and Miller, 1994). 
They also reported that there is a genetic basis to the ability of salmonellae to invade, 
especially S. enterica Typhimurium. 
Although they did not explore these issues in terms of NTS resistant to antibiotics, the 
factors pertaining to immune compromise and HIV status would be useful to consider as 
possible confounders in the relationship between exposure and outcome in this study. 
1.2.4 Association between TMP-SMX prophylaxis and MDR NTS 
The effectiveness of TMP-SMX as prophylaxis for opportunistic disease in HIV patients 
has been well documented (Anglaret et al, 1999; Wiktor et al, 1999; Grimwade et al, 2004; 
Grimwade et al, 2005). This strategy has been embraced by many countries to reduce 
morbidity and mortality in HIV-infected people by reducing their chances of contracting 
an opportunistic disease. The benefits of TMP-SMX prophylaxis must be weighed against 
the risks of developing resistance to other antibiotics and anti-malarials such as 
sulfadoxine-pyrimethamine (Anglaret et al, 1999; Boeree, 1999; Gill et al, 2004).  
Studies such as that conducted by Martin et al have established a link between TMP-SMX 
usage as prophylaxis against opportunistic illnesses and an increase in TMP-SMX 
resistance in various bacteria (Martin et al, 1999). However, it would appear that little 
consideration has been given to assessing the effects of prophylactic TMP-SMX usage on 
bacterial co-resistance, along with other possible and/or known co-factors. 
Hoge et al investigated antibiotic resistance trends in surveillance data from Thailand and 
found that 40% of NTS isolates were resistant to TMP-SMX (Hoge et al, 1998). However, 
the data was not analysed to determine the prevalence of multi-drug resistance in NTS or 
what other risk factors were associated with MDR NTS.  
A WHO expert panel recognised that TMP-SMX, although effective as a prophylactic 
against opportunistic disease, could still contribute to high rates of bacterial resistance and 
recommended that another antibiotic be used to treat diarrhoeal infections in HIV-infected 
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patients on TMP-SMX prophylaxis while continuing the prophylactic treatment (WHO, 
2006). 
It is therefore important to determine whether there is an association between TMP-SMX 
usage and antibiotic resistance in NTS; and to assess whether other factors modify this 
relationship. An understanding of these issues may facilitate the development of strategies 
to minimize the impact (if any) of TMP-SMX on antibiotic resistance in NTS.  
1.2.5 Laboratory-based surveillance for NTS 
The use of surveillance programs to monitor antimicrobial resistance is well documented 
(APUA, 2003). Surveillance for antimicrobial resistance may include sentinel, 
comprehensive routine and enhanced surveillance methods. Each of these systems has 
their advantages and disadvantages and these are summarized in Table 1. 
Table 1: Comparison of surveillance methodologies 
SURVEILLANCE 
METHOD 
ADVANTAGES DISADVANTAGES 
Sentinel  Relatively inexpensive  Does not provide prevalence 
information – cannot be 
used to influence policy 
Routine  Relatively inexpensive 
 Easily maintained 
 Data can be used to 
document epidemiology of 
disease and antimicrobial 
resistance 
 Can analyse data for trends 
over time 
 Data needs to be interpreted 
cautiously 
 Data collection is prone to 
bias 
Enhanced  Allows for bias to be limited 
(with careful study design 
and sampling methodology) 
 Allows for more detailed 
information (e.g. risk 
factors, clinical outcomes, 
hospitalization period) to be 
collected 
 More costly than routine / 
sentinel 
 Targeted nature, therefore 
cope of information 
collected is narrow 
 Subject to bias introduced 
by sampling and testing 
Surveillance data is prone to bias, especially as regards patient data collection and 
sampling; laboratory data (serotyping and antimicrobial susceptibility), being subject to 
quality assurance procedures, may be more reliable (APUA, 2003; WHO, 2002).  
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In addition, not all cases of disease are detected during routine or enhanced surveillance: 
Alos and co-workers and Hardnett et al described the “burden of illness pyramid” which 
illustrates how the proportion of cases detected and reported in surveillance is a fraction of 
the actual number of people exposed to enteric pathogens (Alos et al, 2004; Hardnett et al, 
2004). 
 
Fig. 1 The “burden of illness pyramid” used by FoodNet to assess the burden of 
foodborne disease in the United States (Alos et al, 2004; Hardnett et al, 2004) 
Several countries have embarked on national surveillance programmes to ascertain the 
prevalence and sources of antibiotic resistance and some of the key findings of these 
programs have been previously addressed in paragraphs 1.2.1 and 1.2.2.  
Blomberg et al examined the implementation of an antimicrobial resistance surveillance 
program at a tertiary hospital in Tanzania (Blomberg et al, 2004). They reported that 
laboratory-based surveillance is a good method of collecting antimicrobial resistance data, 
especially for purposes of applying this data locally, i.e. in choosing what would be an 
effective treatment against a particular organism. They affirmed that the data furnished by 
surveillance programs are also useful for assessing trends in antimicrobial resistance, but 
also pointed out certain inherent limitations in antimicrobial resistance surveillance such 
as selection bias and standardization of tests and data collection methodologies. Blomberg 
et al also found laboratory-based surveillance coupled with effective software to be a 
useful and cost-effective tool for gauging antimicrobial resistance prevalence and patterns. 
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The National Health Laboratory Services (NHLS) of South Africa established the Enteric 
Diseases Reference Unit (EDRU) to conduct routine surveillance for a range of enteric 
pathogens and to monitor antimicrobial resistance in diarrhoeagenic pathogens (von 
Gottberg et al, 2002). In addition, ten surveillance centres across the nine provinces of 
South Africa were identified and strengthened to conduct enhanced surveillance for 
diarrhoeal disease – this would include collecting additional information such as HIV 
serostatus, usage of cotrimoxazole prophylaxis, etc. This is of particular relevance in the 
face of widespread use of antimicrobials in general and in the treatment of the HIV / AIDS 
in adults and children. 
It must be emphasized that the information gained in antimicrobial resistance surveillance 
programmes is used to quantify resistance rates of various bacteria to a range of antibiotics 
and to assess the prevalence of antibiotic resistance amongst the various bacterial 
serotypes. Few of these studies have examined the actual associations between various 
factors and antibiotic resistance.  
1.3 Aim 
This study was a secondary analysis of data collected by the EDRU as part of a national 
antibiotic surveillance programme for the years 2003, 2004 and 2005. The primary aim of 
this analysis was to show whether there is an association between the use of TMP-SMX 
prophylaxis and multidrug-resistance in NTS in participants in the enhanced surveillance 
programme for invasive diarrhoeal disease in South Africa from 2003 to 2005. 
1.4 Objectives 
The objectives of this study were to: 
 Determine whether there is an association between prophylactic use of TMP-SMX 
and multi-drug resistant NTS infection 
 Establish whether immune-compromised status and other factors modify the 
relationship between TMP-SMX resistance and invasive / non-invasive type of 
NTS infection  
 Establish whether these associations vary by province 
 Quantify the resistance rates of NTS, in total and by serotype, to a range of 
antibiotics (to establish a baseline prevalence of antibiotic resistance in NTS in 
South Africa) 
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1.5 Problem statement 
Antibiotic resistance is an increasing public health problem for various reasons, ranging 
from its ease of availability and the frequency of its use in agriculture to over-prescribing 
and misuse (EMEA, 1999; School of Public and Community Health, Washington, 2000; 
Tambic and Andrasevic, 2002). This has far-reaching implications as the development of 
new antibiotics has not kept pace with the emerging resistance problem, and fewer 
effective treatments are available. In turn, the costs of healthcare are being pushed up as 
people require more expensive antibiotics and even hospitalization for infections which 
could previously have been treated with simpler, less expensive antibiotics (EMEA, 1999; 
School of Public and Community Health, Washington, 2000; Tambic and Andrasevic, 
2002). 
There is also an increasing trend of nosocomial and community-acquired infection patterns 
in both developed and developing countries, which further impacts on public healthcare 
systems (Tambic and Andrasevic, 2002; Yalcin et al, 2003). It is therefore important to 
determine whether there is an association between TMP-SMX usage and antibiotic 
resistance in NTS; and to assess whether other factors modify this relationship. An 
understanding of these issues may facilitate the development of strategies to minimize the 
impact (if any) of TMP-SMX on antibiotic resistance in NTS.  
As far as can be ascertained, this was the first study of its kind on NTS in South Africa, 
and given the increasing reliance on antibiotics for the treatment of tuberculosis and HIV, 
and the emergence of hospital-acquired resistant infections, the results could form the 
basis of research that would have far-reaching implications for public health policy and 
treatment regimens. 
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2.0 METHODS  
2.1 Study population 
For the analysis of resistance prevalence, the study population was drawn from patients in 
over one hundred public and private hospitals, across all nine provinces in South Africa, 
who have a positive culture for salmonella as per the EDRU Enhanced Surveillance 
Protocol, Appendix A (von Gottberg et al, 2002). For the case-control analysis assessing 
the association of TMP-SMX prophylactic use and MDR-NTS, data from the enhanced 
surveillance sites was used. These sites were expanded over the period of data collection 
and Table 2 lists the enhanced sites that contributed isolates per surveillance year that 
were analysed in this study. 
Table 2: Enhanced surveillance sites in South Africa between 2003 and 2005 
ENHANCED SURVEILLANCE SITES CONTRIBUTING ISOLATES 200
3 
200
4 
2005
Charlotte Maxeke Johannesburg 9 9 9 
Chris Hani Baragwanath 9 9 9 
King Edward VIII 9 9 9 
Groote Schuur / Red Cross 9 9 9 
Tygerberg / 9 9 9 
Dr George Mukhari / Medunsa 9 9 9 
Universitas / Pelonomi 9 9 9 
Rob Ferreira / Themba 9 9 9 
Mthatha 9 9 9 
Polokwane  9 9 
Tshwane / University of Pretoria  9 9 
Addington / RK Khan / Prince Mshiyeni  9 9 
Mankweng  9  
2.2 Study design 
The study design was a cross-sectional study, with outcome defined as persons infected 
with multi-drug resistant or susceptible NTS.  
2.3 Sampling strategy 
This study was a secondary analysis of data collected by the EDRU as part of a national 
antibiotic surveillance programme for the years 2003, 2004 and 2005. The surveillance 
programme has both a routine passive component for serotyping and antimicrobial 
susceptibility testing of all positive culture salmonella specimens obtained from hospital 
admissions in South Africa, as well as an enhanced component for invasive specimens. 
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For 2003, nine enhanced sites operated in eight provinces, expanding to sixteen sites in all 
nine provinces by the end of 2005. 
2.4 Variables 
2.4.1 Exposure 
The exposure of interest was the use of TMP-SMX as prophylaxis. This variable was 
initially recorded as Yes / No and was recoded as a binary variable (0=No, 1=Yes) for this 
study.  
2.4.2 Outcome 
Tabulating the primary exposure against isolates resistant to more than one antibiotic 
showed that all patients for whom prophylactic TMP-SMX usage was known were 
resistant to more than one antibiotic (meaning that there would have been no controls for 
the analysis if MDR was defined as “being resistant to more than one antibiotic). It would 
therefore not have been feasible to consider multi-drug resistance in this manner.  
Accordingly, the definition of multi-drug resistance was refined in terms of the multi-drug 
resistance patterns for salmonella that were identified in earlier research (Glynn et al, 
1998; Helms et al, 2002; Rabatsky-Ehr et al, 2004; Helms et al, 2005). Multi-drug 
resistant isolates were defined as those isolates exhibiting one of four resistance patterns: 
ACSSuT, ACKSSuT, ACSSuTNx or AKSSuT. In addition, a category for all isolates that 
exhibited at least one of these MDR patterns was created. Binary variables were created 
for each of the resistance patterns examined, and these were coded as 0=No for isolates 
susceptible to at least one but not all, of the antibiotics in the pattern and 1=Yes for 
isolates resistant to all antibiotics in the pattern. 
For the case control analysis, cases were defined as a culture-confirmed diagnosis of NTS 
infection, made at the referring diagnostic laboratory as per the EDRU’s enhanced 
surveillance protocol, exhibiting one or more of the MDR patterns. Controls would be 
defined as culture-confirmed NTS isolates without any of these four resistance patterns. 
2.4.3 Confounders / other explanatory variables 
2.4.3.1 Demographic factors 
Age was recalculated in years, using dates of birth and specimen collection preferentially, 
followed by age information recorded in the absence of a date of birth. Age was then 
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recoded into groups starting with <1 year, 1 to 4 years and then in ten-year groups up to 
age 64, with ≥65 years being the last group. 
Sex was recoded from M and F to 0=male and 1=female respectively. 
Province was recoded from one to nine as a nominal variable, to facilitate statistical 
analysis. Isolates were received from each province throughout the period of surveillance. 
2.4.3.2 Clinical variables 
HIV status was recoded from Yes / No / Positive / Negative / Unknown to a binary 
variable (0=Negative, 1=Positive, Unknown=.) 
Similarly prior antibiotic use in the preceding two months was recoded from No / Yes to a 
binary variable following the convention 0=No, 1=Yes. 
ESBL production was also recoded as a binary variable (0=No, 1=Yes) 
During data collection and entry, invasive specimens were classified as those isolated from 
cerebrospinal fluid, blood culture, pleural fluid, joint fluid or pus (if from a retro-
peritoneal abcess). For the purposes of this analysis, specimens were recoded into a binary 
variable (1=Yes/0=No) based on the existing variable for invasive isolates. 
For other immune compromise, a wide range of conditions were recorded and this variable 
was recoded as follows: 
 0= none 
 1= chronic disease (known to have diabetes, renal failure, cardiac failure, 
coronary artery disease, heart disease or systemic lupus erythematosus) 
 2= known to have tuberculosis 
 3= other (known to be on immunosuppressive treatment, having cancer or 
immunosuppressed for organ transplant purposes, or malnourished, i.e. having 
kwashiorkor or marasmus) 
2.4.3.3 Laboratory data 
Antimicrobial susceptibility was ascertained using Clinical and Laboratory Standards 
Institute (CLSI) resistance testing and susceptibility breakpoints for the minimum 
inhibitory concentrations of antibiotics measured using E-tests (AB-Biodisk, Solna, 
Sweden) and disk diffusion diameters (Mast Diagnostics, Mersey, UK) for measurement 
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of ESBL production. The variables with susceptibility information was recoded by 
classifying isolates as susceptible (S) or resistant (R) according to CLSI MIC breakpoints 
(Wayne, 2003). Isolates with intermediate levels of resistance were recoded as resistant.  
During 2003 to 2005, more than eighty salmonella serotypes were identified according to 
the Kaufmann-White scheme used by the reference laboratory (Kauffman, 1951). The five 
most prevalent serotypes were retained as individual categories (1=Typhimurium, 
2=Isangi, 3=Enteritidis, 4=Species, 5=Dublin), with all the remaining serotypes being 
reclassified as “6=Other”. 
2.5 Data collection 
Surveillance officers collected data on case report forms (CRFs) compiled from laboratory 
and clinical records (see Appendix B) at specified sites around South Africa as set out in 
the enhanced surveillance protocol. The data was supplemented by information from 
patient and family interviews, where possible, for the isolates from the enhanced 
surveillance sites. These CRFs were routed with the isolates to the central reference 
laboratory in Johannesburg. The data included on these case report forms were basic 
demographic data (age, sex, place of residence / province). In addition, clinical data such 
as HIV status, TMP-SMX use, information on other immune-compromising conditions 
such as tuberculosis (TB), cancer, preparation for or recent transplant, laboratory 
confirmation of serotype, and recent antibiotic use was recorded. Resistance to antibiotics 
quantified in terms of minimum inhibitory concentrations and disk diffusion diameters 
reflecting extended spectrum beta-lactamase (EBSL) production were recorded on 
separate laboratory cards at the reference laboratory and attached to the CRFs along with 
other relevant information (such as the patients’ chart notes).  
2.6 Data entry 
The information in the CRFs and the accompanying laboratory cards for each year were 
manually entered into an EpiInfo version 6.0 database (Centers for Disease Control and 
Prevention, Atlanta, Georgia). Single data entry was performed (i.e. each record was only 
entered once, no second entry was done for comparison and error-checking). Any errors 
detected during quality control were corrected in writing on the CRFs and laboratory cards 
and manually corrected on the EpiInfo databases. 
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2.7 Data cleaning 
The EpiInfo databases for each of the years of interest were exported in DBIV format and 
then re-imported into a blank MS Access database for cleaning. Relevant fields were 
identified and selected for inclusion in the final table for analysis. Data from the three 
tables were merged into one. 
Using a series of queries, range checks were carried out to identify possible errors and 
recoding was carried out. Certain logic checks such as recoding of resistance / 
susceptibility based on MIC breakpoints and making sure that specimen collection date 
did not pre-date a patient’s date of birth were done.  
Duplicate, recurrent and mixed serotype isolates were identified, categorised and coded as 
such. The records for each of these observations were reviewed. True duplicates were 
identified as isolates with the same hospital number, same collection date or collected 
within a 21-day period of each other, same/different specimen, serotype and susceptibility 
testing results. Recurrent episodes were identified as isolates from patients with the same 
hospital number, name and serotype, collected more than 21 days apart. Mixed serotypes 
were defined as isolates from the same patient (as identified by hospital number and 
name), with the same collection date or within a 21-day period, same or different 
specimen from which more than one serotype was cultured with different susceptibility 
test results. 
As recurrent episodes made up a small proportion (3.11%) of all isolates, they were treated 
as individual cases for the analysis of resistance prevalence. This is important because re-
admissions add to the burden on the health care system. They were excluded for the case-
control and regression analyses and the calculation of annual disease incidence. 
Resistance to imipenem has not yet been observed in NTS in South Africa (personal 
communication, K Keddy, 2009), therefore the laboratory cards of isolates with MICs 
which implied imipenem resistance were examined – all but one (which was excluded 
from analysis) were errors due to data entry.  
Isolates for which antimicrobial susceptibility results for a particular year were incomplete 
were excluded from the analysis. 
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2.8 Statistical analysis 
Univariate analysis was carried out for each variable, to build a description of the study 
sample. For continuous or discrete variables, means, medians, interquartile ranges, 
minimum and maximum values were determined. Histograms with normal density plots 
were produced for age and the key antibiotic MICs. Categorical and binary data were 
tabulated and proportions were calculated. Appropriate graphs were used to present 
variables of interest. Annual NTS incidence rates (calculated as annual diagnosis rates per 
100000 population) were determined using mid-year population estimates for South Africa 
for each year of surveillance (Statistics South Africa, 2003; Statistics South Africa, 2004; 
Statistics South Africa, 2005). Standard 95% confidence intervals for these incidence rates 
were determined using immediate commands in Stata. 
Bivariate analyses of the outcome variables with the primary exposure, i.e. TMP-SMX 
prophylaxis, as well as with age (grouped), sex, province, immune-compromise status, 
antibiotic use in the last two months were carried out using χ² tests to determine if there 
were any significant differences in proportion of outcome with exposure at the 95% 
significance level. Fisher’s exact p values were reported for tabulations with cells having 
an n of five or less. 
Student’s t-tests were used to determine if there were any differences in age between 
controls and each of the case types.  
Mantel-Haenszel methods were used to test for interaction between exposure variables or 
effect modification of the primary associations by covariates, at the 95% level of 
significance. 
Univariate logistic regression models of outcome (each of the MDR patterns) with each 
exposure factor in turn were run. Multivariate logistic regression models, including all 
exposure variables significant at the 10% level in the unvariate analysis, were developed. 
Likelihood ratio tests at the 5% level of significance were used to assess the fit of each 
multivariate model. 
To investigate the relationship between resistance to TMP-SMX and invasive NTS, a 
univariate regression model was constructed. I attempted to fit a multivariate regression 
model to investigate the relationship between TMP-SMX resistance and invasive disease. 
However, running the Stata command for this model yielded an error message, because a 
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positive outcome (i.e. resistant to TMP-SMX=yes) predicted the data perfectly, i.e. all 
invasive isolates were resistant to TMP-SMX. 
All statistical analysis was carried out using Stata version 10. Graphs were prepared using 
either Stata 10 or MS Excel 2003. 
2.9 Ethical clearance 
An application for clearance of the enhanced surveillance protocol from the Wits Health 
Research Ethics Committee was applied for and originally granted under protocol 
clearance number. M02 – 10 – 42. A separate application was made to conduct this 
secondary analysis, this was granted and allocated protocol number M071028. Copies of 
both letters from the ethics committee are attached (Appendix C). 
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3.0 RESULTS 
3.1 Study population – Number of isolates analysed 
For the period 01/01/2003 to 31/12/2005, 4765 viable salmonella (both typhoidal and non-
typhoidal) isolates were received at the EDRU’s reference laboratory in Sandringham. Of 
these, 4402 non-typhoidal salmonella (NTS) isolates were included in the analyses for 
antimicrobial resistance prevalence, after excluding isolates for which MICs were 
incomplete / not available and duplicate isolates.  
TMP-SMX usage was ascertained for 772 patients and contributed in part or total to the 
case-control analyses done. Figure 3.1 shows how the final number of isolates included in 
these analyses was arrived at. The case control and regression analyses excluded recurrent 
episodes of infection and therefore the maximum sample size for this part of the analysis 
was 4265. As susceptibilities to kanamycin were not determined during 2003, the 
maximum sample size for the ACKSSuT and AKSSuT MDR patterns was 552. To 
facilitate reading of this paper, the total sample size for each analysis is stipulated in each 
table in which results are presented. 
3.2 Missing data 
Also presented in Table 3.1, is information on the extent of missing data within the 
dataset. From the demographic variables, both age and sex have missing values, which 
make up less than 10% of the data for each variable and is within the acceptable limit for 
missing data (personal communication, Dr R Kellerman, 2008).  
The variables measuring HIV status, TMP-SMX prophylactic use, other immune 
compromise and prior antimicrobial use had a high percentage of missing data (80.61-
88.25%) on initial inspection. However, it must be borne in mind that data for these 
variables is not collected for all isolates and should only be available for the isolates from 
the enhanced sites. For these variables it was ascertained that the majority of data came 
from the enhanced surveillance sites as opposed to the routine surveillance sites: 
 Other immune compromise – 493/501 (98.40%) of responses were from records of 
isolates from the enhanced surveillance sites at which this information was routinely 
sourced 
 HIV status – 803/827 (97.10%) of responses were from the enhanced surveillance sites 
 Prior antibiotic usage – 722/742 (97.30%) of responses were from the enhanced 
surveillance sites 
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Fig. 3.1 Flow diagram showing derivation of analysis samples 
4765 isolates received between 
01/01/2003 and 31/12/2005 
311 typhoidal salmonella 
isolates excluded 
4454 non-typhoidal 
salmonella isolates 
17 isolates for which 
MICS could not be 
determined excluded
10 isolates with 
incorrect / incomplete 
MICs excluded 
ACKSSuT 
84 cases 
467 controls
772 isolates from patients for whom TMP-SMX 
usage was determined (218 on TMP-SMX) 
4402 isolates with 
complete MICs analysed 
for resistance prevalence 
(descriptive statistics) 
ACSSuT 
183 cases 
589 controls
4429 non-duplicate 
isolates used for analysis 
25 duplicate isolates 
excluded from analysis 
ACSSuTNx 
103 cases 
669 controls
AKSSuT 
115 cases 
436 controls
>1 MDR pattern 
214 cases 
558 controls
137 recurrent episodes excluded from 
case-control and regression analysis 
Maximum of 4265 isolates used 
for analysis of  resistance 
prevalence and study population 
demographics
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 TMP-SMX prophylactic use – 750/772 (97.15%) of responses were from the enhanced 
surveillance sites 
As such, the percentage of missing data is reduced to between 42% for HIV status and 
64% for other immune compromise (since the denominator is now reduced to 1386 
isolates from the enhanced sites instead of 4265 for the entire surveillance programme). 
This is still a high proportion of missing data, but it is important to note that for these 
variables, responses recorded as “Unknown” were recoded as “Missing” in order to create 
dichotomous variables for the analyses performed. Table 3.1 shows the proportion of 
missing data for each variable in the dataset. 
3.3 Study population – Demographics of patients contributing isolates 
In order to develop a picture of the overall study population, univariate analysis was 
conducted to obtain frequencies/percentages of the demographic, clinical and laboratory 
data. These findings are presented in Table 3.1.  
3.3.1 Age 
The mean age of patients from whom NTS isolates were obtained was 19.92 years (95% 
CI 19.27 – 20.57) and 50% of patients, for whom age was ascertained, were aged 13 years 
or less, as expected. The age distribution of patients from whom isolates were obtained 
was positively skewed (Figure 3.2).  
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Figure 3.2 Frequency distribution of age (with normal density plot) 
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3.3.2 Gender 
1983 of 3917 isolates (49.37%) were from female patients. 
3.3.3 Province 
The majority of isolates 2119 out of 4265 (49.68%) came from the Gauteng province, 
followed by the Western Cape (15.97%) and KwaZulu-Natal (13.51%). 
3.3.4 On TMP prophylaxis  
Of the 772 patients (18.10% of total dataset) for whom information was ascertained on 
prophylactic usage of TMP-SMX, 28.24% were confirmed to be using TMP-SMX for 
prophylactic purposes. In addition, 99.49% of patients on TMP-SMX prophylaxis were 
known to be HIV positive. 
3.3.5 HIV status 
Of the 827 patients for whom HIV status was determined, 750 (90.69%) were HIV 
positive.  
3.3.6 Prior antibiotic treatment 
Of the 742 patients for whom prior antibiotic usage was assessed, 160 (21.56%) were 
treated with antibiotics in the two months preceding admission. 
3.3.7 Site of infection 
Forty eight percent (2047/4265) of isolates were classified as being from patients with 
invasive NTS. 
3.3.8 Other immune compromise 
Tuberculosis was the next most prevalent immune compromise factor other than HIV 
status, and 97.24% of patients with TB were also HIV positive. The majority, 68.04%, of 
patients with other immune compromise factors (including TB) were HIV positive. 
Consequently, although the proportion of each type of non-HIV immune compromise is 
reported in subsequent tables of the results of the bivariate analyses for each MDR pattern, 
this factor was not included in the regression analysis. 
3.3.9 Resistance to TMP-SMX 
Of 4265 isolates tested, 55.71% were resistant to TMP-SMX, while 167 of 218 (76.61%) 
patients on TMP-SMX prophylaxis produced isolates that were resistant to it. 
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3.3.10 ESBL-producers 
30.88% of isolates were ESBL-producers. 
3.3.11 Serotype 
The most prevalent serotype was S. enterica Typhimurium (49.14% of isolates over the 
period of surveillance), while the next most common serotype was S. enterica Isangi 
(1023/4265 isolates or 23.99%). S. enterica Dublin was the least prevalent serotype, 
making up just 2.98% of the 4265 isolates tested. 
Table 3.1: Demographic and clinical characteristics of all participants  
 All participants n (%) 
Mean age (n=3930) 19.92 (95% CI 19.27 – 20.57) 
Age group (n=4265) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
Missing 
 
1114 (26.12) 
635 (14.89) 
235 (5.51) 
230 (5.39) 
667 (15.64) 
553 (12.97) 
263 (6.17) 
137 (3.21) 
96 (2.25) 
335 (7.85) 
Sex (n=4265) 
Female 
Male 
Missing 
 
1983 (46.49) 
1934 (45.35) 
348 (8.16) 
Province (n=4265) 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
 
417 (9.78) 
124 (2.91) 
2119 (49.68) 
576 (13.51) 
67 (1.57) 
169 (3.96) 
11 (0.26) 
101 (2.37) 
681 (15.97) 
TMP-SMX prophylaxis (n=4265) 
No 
Yes 
Missing 
 
554 (12.99) 
218 (5.11) 
3493 (81.90) 
Antibiotic treatment in previous 2 months (n=4265) 
No 
Yes 
Missing 
 
582 (13.65) 
160 (3.75) 
3523 (82.60) 
HIV status (n=4265) 
Negative 
Positive 
 
77 (1.81) 
750 (17.58) 
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Missing 3438 (80.61) 
Invasive (n=4265) 
No 
Yes 
 
2218 (52.00) 
2047 (48.00) 
Other immune compromise (n=4265) 
TB 
Chronic disease 
Other immune suppression 
None 
Missing 
 
294 (6.89) 
25 (0.59) 
120 (2.81) 
62 (1.45) 
3764 (88.25) 
Resistant to TMP-SMX (n=4265) 
Yes 
No  
 
2376 (55.71) 
1889 (44.29) 
ESBL-producers (n=4265) 
No 
Yes 
 
2948 (69.12) 
1317 (30.88) 
Serotype (n=4265) 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
 
2096 (49.14) 
1023 (23.99) 
273 (6.40) 
202 (4.74) 
127 (2.98) 
544 (12.75) 
3.4 Annual incidence of NTS for  2003-2005 
A total of 1070, 1505 and 1690 single (i.e. non-recurrent) NTS isolates were received by 
the reference laboratory for the years 2003, 2004 and 2005 respectively. Of these, 
521(48.69%) 732 (48.64%) and 794 (46.98%) isolates were invasive in the years 2003, 
2004 and 2005 respectively. This translated to annual incidence rates of 1.12 invasive non-
typhoidal salmonella cases per 100000 (95% CI 1.03-1.22/100000) people for 2003, 
1.57/100000 for 2004 (1.46-1.69/100000) and 1.69/100000 (1.58-1.82/100000) for 2005.  
3.5 Prevalence of resistance rates of NTS to antibiotics tested 
Histograms with normal density plots revealed that the MICs of the antibiotics tested 
followed either skewed or bimodal (with observations peaked around the breakpoint 
values) distributions. These graphs are presented in Figure 3.3.
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Figure 3.3 Frequency distributions of MICs for antibiotics tested 
(a) – Ampicillin, (b) – Chloramphenicol, (c) – Streptomycin, (d) – Sulfamethoxazole, 
(e) – Tetracycline, (f) –Kanamycin, (g) – Nalidixic acid, (h) – Cotrimoxazole,  (i) – 
Ciprofloxacin 
Basic descriptive statistics of the minimum inhibitory concentrations of the antibiotics 
tested during the period of surveillance are presented in Table 3.2. The NTS isolates 
demonstrated low rates of resistance to ciprofloxacin and high rates of resistance to 
ampicillin and sulfamethoxazole for the period surveyed. Imipenem resistance was not 
observed during the period surveyed. 
Table 3.2 MICs using E-tests for NTS isolates received during 2003 – 2005 
Antibiotic Mean 
µg/ml 
Median Range Resistance rate 
(%) 
N 
Ampicillin 155.06 256 0.023-256.30 60.87 4265 
Augmentin 8.05 4 0.032-632 28.16 4265 
TMP-SMX 18.64 32 0.002-256 55.71 4265 
Trimethoprim 19.45 32 0.002-3200 55.90 4265 
Sulfamethoxazole 748.26 1024 0.064-4824 75.85 4265 
Chloramphenicol 107.04 6 0.012-6024 43.87 4265 
Nalidixic acid 96.08 4 0.012-1024 37.47 4265 
Ciprofloxacin 0.24 0.016 0.003-125 0.98 4265 
Tetracycline 88.30 12 0.012-3256 55.43 4265 
Kanamycin 58.33 4 0.19-2566 38.25 3195 
Streptomycin 111.25 48 0.125-2596 48.04 4265 
Imipenem 0.25 0.19 0.008 - 4 0 3195 
Ceftriaxone 34.86 0.19 0.004-256 20.42 4265 
Cefepime 31.30 8 0.016-600 43.29 1587 
Ceftazidime 77.81 0.50 0.019-256 33.76 4265 
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3.6 Distribution of resistance rates by province, serotype and year 
3.6.1 Distribution of resistance by province 
The distribution of resistance rates by province shows consistently lowest resistance rates 
(0.98%) to ciprofloxacin across all provinces in South Africa (see Table 3.3). Overall, the 
highest rates of resistance observed across all provinces were to sulfamethoxazole, with 
75.85% of isolates submitted exhibiting resistance to it. 30.88% of NTS isolates were 
ESBL-producers, and 55.71% of isolates were resistant to TMP-SMX. Resistance to 
imipenem was not observed in the 3195 isolates tested from 2003 to 2005. 
Table 3.3 Distribution of antibiotic resistance rates by province 
  Antibiotic  
 
 
 
 
 
 
 
 
 
Province A
m
pi
ci
lli
n 
(n
=4
26
5)
 
A
ug
m
en
tin
 (n
=4
26
5)
 
T
M
P-
SM
X
 (n
=4
26
5)
 
T
ri
m
et
ho
pr
im
 (n
=4
26
5)
 
Su
lfa
m
et
ho
xa
zo
le
 (n
-4
26
5)
 
C
hl
or
am
ph
en
ic
ol
 (n
=4
26
5)
 
N
al
id
ix
ic
 a
ci
d 
(n
=4
26
5)
 
C
ip
ro
flo
xa
ci
n 
(n
=4
26
5)
 
T
et
ra
cy
cl
in
e 
(n
-4
26
5)
 
K
an
am
yc
in
 (n
=3
19
5)
 
St
re
pt
om
yc
in
 (n
=4
26
5)
 
C
ef
tr
ia
xo
ne
 (4
26
5)
 
C
ef
ep
im
e 
(n
=1
58
7)
 
C
ef
ta
zi
di
m
e 
(n
=4
26
5)
 
E
SB
L
s (
42
65
) 
Eastern Cape 62.83 17.03 61.39 61.63 77.94 58.27 39.09 0.24 68.35 40.92 56.83 25.42 44.39 52.76 49.16
Free State 45.97 13.71 40.32 40.32 66.13 43.55 40.32 1.61 43.55 22.58 41.13 27.42 45.95 31.45 28.23
Gauteng 68.29 39.08 62.48 62.62 80.08 42.80 39.03 0.47 53.23 46.82 50.26 22.98 44.64 30.91 27.37
KwaZulu-
Natal 
56.60 25.00 53.47 53.65 74.48 39.58 34.38 3.82 56.94 39.81 42.71 20.66 49.75 32.47 30.38
Limpopo 32.84 11.94 31.34 31.34 56.72 32.84 5.97 1.49 38.81 21.54 28.36 7.46 60.00 20.90 20.90
Mpumalanga 34.32 14.79 24.26 25.44 56.21 18.93 5.33 0 25.44 14.29 13.02 2.37 28.57 2.96 2.37 
Northern 
Cape 
36.36 9.09 36.36 36.36 72.73 27.27 9.09 0 27.27 30.00 36.36 27.27 66.67 27.27 27.27
North West 58.42 19.80 50.50 50.50 76.24 44.55 28.71 0 50.50 33.77 44.55 34.65 57.14 39.60 34.65
Western Cape 53.01 12.78 47.14 47.28 71.07 49.49 46.55 0.88 65.49 20.31 52.86 11.45 31.79 40.68 39.06
Total 60.87 28.16 55.71 55.90 75.85 43.87 37.47 0.98 55.43 38.25 48.04 20.42 43.29 33.76 30.88
3.6.2 Distribution of resistance by serotype 
Table 3.4 shows the resistance rates by serotype for the period 2003 to 2005, generally, 
low rates of resistance to ciprofloxacin were observed. The S. enterica Isangi isolates had 
very high resistance rates to all antibiotics tested except for ciprofloxacin (0.39%). This 
holds true for S. enterica Typhimurium as well with 1.53% of isolates resistant to 
ciprofloxacin. 
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Table 3.4: Distribution of antibiotic resistance rates by NTS serotype (%) 
Antibiotic  
 
 
 
 
 
 
 
 
Serotype  A
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40
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=4
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 (n
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40
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d 
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=4
40
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C
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flo
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n 
(4
40
2)
 
T
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in
e 
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=4
40
2)
 
K
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yc
in
 (n
=3
30
3)
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re
pt
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yc
in
 (n
=4
40
2)
 
C
ef
tr
ia
xo
ne
 (n
=4
40
2)
 
C
ef
ep
im
e 
(n
=1
66
4)
 
C
ef
ta
zi
di
m
e 
(n
=4
40
2)
 
E
SB
L
s (
n=
44
02
) 
Typhimurium 65.46 32.16 57.06 57.35 80.68 34.40 21.37 1.5350.48 46.13 42.56 14.89 27.66 18.03 17.89
Isangi  97.75 42.62 95.41 95.41 98.04 98.14 90.13 0.3998.14 56.11 96.09 49.07 51.06 95.70 84.65
Enteritidis 9.16 1.47 9.89 9.52 36.63 7.33 46.15 0.7317.22 0.48 7.69 2.20 18.18 1.83 2.20 
Species 47.52 22.28 39.60 40.10 67.33 23.27 21.29 1.4940.59 35.82 28.71 12.38 54.55 14.85 12.87
Dublin 5.51 1.57 6.30 6.30 20.47 3.94 3.94 0 6.30 1.11 6.30 0 0 0 0 
Other  17.65 7.35 16.36 16.73 51.29 13.60 9.93 0.1830.33 4.95 15.99 4.78 40.68 8.82 8.09 
3.6.3 Distribution of resistance by year of surveillance 
Fig 3.4 shows the distribution of serotypes per year of surveillance from 2003 to 2005. S. 
enterica Typhimurim was the most predominant serotype identified, making up 49.14% of 
the total isolates serotyped over that period. S. enterica Dublin was the least prevalent 
serotype, identified from 2.98% of isolates tested between 2003 and 2005. 
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Fig 3.4 Distribution of NTS serotypes by year for the period studied  
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3.6.4 Prevalence of MDR patterns per year of surveillance 
The prevalence of each MDR resistance pattern was plotted by year and this is presented 
in Fig 3.5. There were slight decreases in the prevalence of the ACSSuT resistance pattern 
from 38.13% to 32.13% between 2003 and 2005, and this was significant at the 95% level 
(χ² p=0.003). Prevalence of ACSSuTNx multi-drug resistance also decreased from 29.35% 
in 2003 to 23.59% in 2004, but rose again to 26.33% in 2005; these differences in the 
prevalence of the ACSSuTNx pattern were also significant (χ² p=0.004). The prevalence 
of ACKSSuT and AKSSuT resistance in NTS decreased significantly from 23.72% in 
2004 to 16.69% in 2005 (p=0.000) and 26.51% to 20.71% respectively (p=0.000).  
Prevalence of the ACKSSuT and AKSSuT resistance patterns was not calculated for 2003, 
as susceptibility testing of isolates for that year excluded the antibiotic kanamycin. 
Although the prevalence of isolates with one or more MDR patterns is seen to decrease 
from 38.13% to 35.68 between 2003 and 2004, then increases slightly to 36.15% in 2005, 
these differences were not statistically significant (p=0.417).  
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Fig 3.5 Distribution of MDR patterns per year of surveillance 
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3.7 Univariate analysis of TMP-SMX usage and MDR NTS 
3.7.1 Relationship between ACSSuT and prophylactic use of TMP-SMX 
A summary of the univariate analysis of the ACSSuT multi-drug resistance pattern with 
each risk factor / explanatory variable is presented in Table 3.5. Findings in respect of 
each of these factors are highlighted below. 
3.7.1.1 Demographic factors 
 Age: Unpaired t-tests revealed that the mean age of ACSSuT cases was 10.20 years 
(9.27 – 11.13) and was significantly lower than that of controls, who had an average 
age of 24.76 years (23.97 – 25.55), p=0.0000.  
 Using Chi-squared tests, age and province of origin of isolate were significantly 
associated with the ACSSuT resistance pattern at p≤0.05 
3.7.1.2 Clinical factors 
 On TMP-SMX prophylaxis: Of the 772 cases for whom prophylactic use of TMP-
SMX was ascertained, 60 (32.79%) were on TMP-SMX prophylaxis. Although being 
on TMP-SMX was not significantly associated with outcome (χ² p>0.05). 
 Prior antibiotic treatment and site of infection were also significantly associated with 
ACSSuT resistance (χ² p=0.000).  
3.7.1.3 Microbiological factors 
 TMP-SMX resistance, ESBL-production and serotype were associated with ACSSuT 
resistance at p≤0.05 during univariate analysis using Pearson’s Chi-squared test. 
Table 3.5 Characteristics of cases and controls with the ACSSuT resistance pattern  
 Controls n (%) Cases n (%) p value 
Mean age 24.76 (23.97-25.55) 10.20 (9.27-11.13) 0.0000 
Age group (n=3930) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
 
484 (18.45)  
344 (13.11) 
175 (6.67) 
195 (7.43) 
542 (20.66) 
459 (17.49) 
228 (8.69) 
115 (4.38) 
82 (3.13) 
 
630 (48.24) 
291 (22.28) 
60 (4.59) 
35 (2.68) 
125 (9.57) 
94 (7.20) 
35 (2.68) 
22 (1.68) 
14 (1.07) 
0.0000 
Sex (n=3917) 
Female 
Male 
 
1309 (49.83) 
1318 (50.17) 
 
625 (48.45) 
665 (51.55) 
0.417 
Province (n=4265)   0.0001 
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Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
205 (7.27) 
84 (2.98) 
1455 (51.63) 
390 (13.84) 
53 (1.88) 
160 (5.68) 
9 (0.32) 
68 (2.41) 
394 (13.98) 
212 (14.65) 
40 (2.76) 
664 (45.89) 
186 (12.85) 
14 (0.97) 
9 (0.62) 
2 (0.14) 
33 (2.28) 
287 (19.83) 
TMP-SMX prophylaxis (n=772) 
No 
Yes 
 
431 (73.17)  
158 (26.83) 
 
123 (67.21)  
60 (32.79) 
0.118 
Prior antibiotic treatment (n=742) 
Yes 
No 
 
105 (18.62) 
459 (81.38) 
 
55 (30.90) 
123 (69.10) 
 
0.001 
HIV positive (n=827) 
Yes 
No 
 
575 (91.13) 
56 (8.87) 
 
175 (89.29) 
21 (10.71) 
0.439 
Site of infection (n=4265) 
Invasive  
Non-invasive 
 
1637 (58.09) 
1181 (41.91) 
 
410 (28.33) 
1037 (71.67) 
0.000 
Other immune compromise (n=501) 
TB 
Chronic disease 
Other immune suppression 
None 
 
218 (56.77) 
22 (5.73) 
96 (25.00) 
48 (12.50) 
 
76 (64.96) 
3 (2.56) 
24 (20.51) 
14 (11.97) 
0.3362 
Resistant to TMP-SMX (n=4265) 
Yes 
No  
 
1000 (35.49) 
1818 (64.51) 
 
1376 (95.09) 
71 (4.91) 
0.000 
ESBL-producer (n=4265) 
Yes 
No  
 
149 (5.29) 
2669 (94.71) 
 
1168 (80.72) 
279 (19.28) 
0.000 
Serotype (n=4265) 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
 
1701 (60.36) 
59 (2.09) 
259 (9.19) 
170 ( 6.03) 
127 (4.51) 
502 (17.81) 
 
395 (27.30) 
964 (66.62) 
14 (0.97) 
32 (2.21) 
0 
42 (2.90) 
0.0001 
1 Stata could not calculate Fisher’s exact p value because of memory requirements 
2 Fisher’s exact p value 
3.7.2 Relationship between ACKSSuT and prophylactic use of TMP-SMX 
Tabulating isolates with the ACKSSuT MDR pattern with each risk factor produced 
results summarized in Table 3.6.  
3.7.2.1 Demographic factors 
 Age: The mean age of ACKSSuT cases was 11.04 years (9.65 – 12.44) compared to 
22.19 years (21.35 – 23.03) for controls, this difference was significant at the 95% 
level (unpaired t-test p=0.0000). There were significant differences in the proportion 
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of cases in each age group (χ² p=0.000), and the majority of cases were from patients 
aged 4 years or younger.  
 There were also significant differences in the distribution of cases and controls 
between the provinces (χ² p=0.000),  
3.7.2.2 Clinical factors 
 Being on TMP-SMX prophylaxis, HIV status, site of infection, other immune 
compromise and prior antibiotic treatment were significantly associated with 
ACKSSuT resistance (χ² p≤0.05). 
3.7.2.3 Microbiological factors 
 TMP-SMX resistance, ESBL-production and serotype were significantly associated 
with ACKSSuT resistance in univariate analysis  (χ² p≤0.05).  
Table 3.6: Characteristics of cases and controls with the ACKSSuT resistance 
pattern 
 Controls n (%) Cases n (%) p value 
Mean age 22.19 (21.35-23.03) 11.04  (9.65-12.44) 0.0000 
Age group (n=3028) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
 
582 (24.07) 
355 (14.68) 
158 (6.53) 
158 (6.53) 
440 (18.20) 
367 (15.18) 
189 (7.82) 
98 (4.05) 
71 (2.94) 
 
281 (46.07) 
133 (21.80) 
30 (4.92) 
14 (2.30) 
66 (10.82) 
52 (8.52) 
18 (2.95) 
8 (1.31) 
8 (1.31) 
0.000 
Sex (n=3103) 
Female 
Male 
 
1222 (49.16) 
1264 (50.84) 
 
295 (47.81) 
322 (52.19) 
0.550 
Province (n=3195) 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
 
212 (8.30) 
79 (3.09) 
1207 (47.24) 
421 (16.48) 
58 (2.27) 
145 (5.68) 
8 (0.31) 
59 (2.31) 
366 (14.32) 
 
113 (17.66) 
14 (2.19) 
288 (45.00) 
114 (17.81) 
7 (1.09) 
2 (0.31) 
2 (0.31) 
18 (2.81) 
82 (12.81) 
0.0001 
TMP-SMX prophylaxis (n=551) 
Yes  
No 
 
118 (25.27)  
349 (74.73) 
 
33 (39.29)  
51 (60.71) 
0.008 
Antibiotic use in last 2 months 
(n=527) 
Yes 
 
 
73 (16.33) 
 
 
31 (38.75) 
0.000 
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No 374 (83.67) 49 (61.25) 
HIV status (n=613) 
Negative 
Positive 
 
54 (10.49) 
461 (89.51) 
 
5 (5.10) 
93 (94.90) 
0.0642 
Site of infection (n=3195) 
Invasive  
Non-invasive 
 
1335 (52.25) 
1220 (47.75) 
 
191 (29.84) 
449 (70.16) 
0.000 
 
Other immune compromise
(n=416) 
TB 
Chronic disease 
Other immune suppression 
None 
 
 
178 (51.59) 
17 (4.93) 
101 (29.28) 
49 (14.20) 
 
 
49 (69.01) 
0 
11 (15.49) 
11 (15.49) 
0.0082 
Resistant to TMP-SMX (n=3195)
Yes 
No 
 
1137 (44.50) 
1418 (55.50) 
 
632 (98.75) 
8 (1.25) 
0.000 
ESBL-producer (n=3195) 
Yes 
No 
 
355 (13.89) 
2200 (86.11) 
 
539 (84.22) 
101 (15.78) 
0.000 
Serotype (n=3195) 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
 
1362 (53.31) 
324 (12.68) 
207 (8.10) 
182 (7.12) 
90 (3.52) 
390 (15.26) 
 
227 (35.47) 
380 (59.38) 
0 
19 (2.97) 
0 
14 (2.19) 
0.0001 
1 Stata could not calculate Fisher’s exact p value because of memory requirements 
2 Fisher’s exact p value 
3.7.3 Relationship between ACSSuTNx and prophylactic use of TMP-SMX 
Table 3.7 summarises results from the univariate analysis of the ACSSuTNx resistance 
pattern with each risk factor.  
3.7.3.1 Demographic factors 
 Age: ACSSuTNx cases were younger than controls, with a mean age of 8.11 years 
(7.13-9.09) compared to 23.90 (23.15-24.65) for controls. This difference was 
significant at the 95% level (unpaired t-test p=0.0000).  
 There were also significant differences in the distribution of cases and controls 
between the provinces (χ² p=0.000) with the majority of cases (41.70%) and controls 
(52.51%) coming from Gauteng. 
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3.7.3.2 Clinical factors 
 On TMP-SMX prophylaxis: 34.95% of cases were on TMP-SMX prophylaxis 
compared to 27.20% of controls. This was not a statistically significant difference (χ² 
p=0.104). 
 Prior antibiotic treatment, other immune compromise and site of infection were 
significantly associated with ACSSuTNx resistance (χ² p≤0.05).  
3.7.3.3 Microbiological factors 
 TMP-SMX resistance, ESBL-production and serotype as they were significantly 
associated with ACSSuTNx resistance  (χ² p≤0.05) 
Table 3.7: Characteristics of cases and controls with the ACSSuTNx resistance 
pattern 
 Controls n (%) Cases n (%) p value 
Mean age 23.90 (23.15-24.65) 8.11 (7.13-9.09) 0.0000 
Age group (n=3930) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
 
597 (20.31) 
395 (13.44) 
189 (6.43) 
211 (7.18) 
592 (20.14) 
502 (17.08) 
245 (8.34) 
122 (4.15) 
86 (2.93) 
 
517 (52.17) 
240 (24.22) 
46 (4.64) 
19 (1.92) 
75 (7.57) 
51 (5.15) 
18 (1.82) 
15 (1.51) 
10 (1.01) 
0.000 
Sex (n=3917) 
Female 
Male 
 
1461 (49.74) 
1476 (50.26) 
 
473 (48.27) 
507 (51.73) 
0.423 
Province (n=4265) 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
 
263 (8.35) 
87 (2.76) 
1654 (52.51) 
414 (13.14) 
66 (2.10) 
167 (5.30) 
10 (0.32) 
78 (2.48) 
411 (13.05) 
 
154 (13.81) 
37 (3.32) 
465 (41.70) 
162 (14.53) 
1 (0.09)* 
2 (0.18) * 
1 (0.09) * 
23 (2.06) 
270 (24.22) 
0.0001 
TMP-SMX prophylaxis (n=772) 
No 
Yes 
 
487 (72.80) 
182 (27.20) 
 
67 (65.05) 
36 (34.95) 
0.104 
Antibiotic use in last 2 months (n=742) 
No 
Yes 
 
513 (79.91) 
129 (20.09) 
 
69 (69.00) 
31 (31.00) 
0.014 
HIV status (n=827) 
Negative 
Positive 
 
63 (8.86) 
648 (91.14) 
 
14 (12.07) 
102 (87.93) 
0.270 
Site of infection (n=4265)   0.000 
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Invasive  
Non-invasive 
1799 (57.11) 
1351 (42.89) 
248 (22.24) 
867 (77.76) 
Other immune compromise (n=501)  
TB 
Chronic disease 
Other immune suppression 
None 
 
254 (58.93) 
25 (5.80) 
102 (23.67) 
50 (11.60) 
 
40 (57.14) 
0* 
18 (25.71) 
12 (17.14) 
0.0862 
TMP-SMX resistant (n=4265) 
Yes 
No 
 
1289 (40.92) 
1861 (59.08) 
 
1087 (97.49) 
28 (2.51) 
0.000 
ESBL-producer (n=4265) 
Yes 
No 
 
367 (11.65) 
2783 (88.35) 
 
950 (85.20) 
165 (14.80) 
0.000 
Serotype (n=3195) 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
 
1924 (61.08) 
130 (4.13) 
271 (8.60) 
178 (5.65) 
127 (4.03) 
520 (16.51) 
 
172 (15.43) 
893 (80.09) 
2 (0.18) * 
24 (2.15) 
0* 
24 (2.15) 
0.0001 
1 Stata could not calculate Fisher’s exact p value because of memory requirements 
2 Fisher’s exact p value 
3.7.4 Relationship between AKSSuT and prophylactic use of TMP-SMX 
A summary of results from the univariate analysis of the AKSSuT resistance pattern with 
each risk factor in turn is presented in Table 3.8.  
3.7.4.1 Demographic factors 
 Age: AKSSuT cases were younger than controls, with a mean age of 13.52 years 
(12.14-14.91) compared to 21.92 (21.06-22.78) for controls. This difference was 
statistically significant (unpaired t-test for equality of means p=0.0000). There were 
significant differences in the proportion of AKSSuT cases in each age group (χ² 
p=0.000), with 61.44% of cases aged 4 years or younger compared to 39.44% of 
controls.  
 Province of origin of isolate was also significantly associated with AKSSuT resistance 
(χ² p≤0.05). 
3.7.4.2 Clinical factors 
 Being on TMP-SMX prophylaxis, prior antibiotic treatment, HIV status, site of 
infection and other immune compromise were significantly associated with the 
AKSSuT resistance pattern (χ² p≤0.05). 
3.7.4.3 Microbiological factors 
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 TMP-SMX resistance, ESBL-producers and serotype were also significantly 
associated with AKSSuT resistance (χ² p 0.05). 
Table 3.8: Characteristics of cases and controls with the AKSSuT resistance pattern 
 Controls n (%) Cases n (%) p value 
Mean age 21.92 (21.06-22.78) 13.52 (12.14-14.91) 0.0000 
Age group n (%) (n=3028) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
 
565 (24.41) 
348 (15.03) 
153 (6.61) 
149 (6.44) 
414 (17.88) 
351 (15.16) 
177 (7.65) 
88 (3.80) 
70 (3.02) 
 
298 (41.80) 
140 (19.64) 
35 (4.91) 
23 (3.23) 
92 (12.90) 
68 (9.54) 
30 (4.21) 
18 (2.52) 
9 (1.26) 
0.000 
Sex (n=3103) 
Female 
Male 
 
1165 (48.99) 
1213 (51.01) 
 
352 (48.55) 
373 (51.45) 
0.836 
Province (n=3195) 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
 
210 (8.59) 
79 (3.23) 
1128 (46.13) 
400 (16.36) 
56 (2.29) 
143 (5.85) 
8 (0.33) 
58(2.37) 
363 (14.85) 
 
115 (15.33) 
14 (1.87) 
367 (48.93) 
135 (18.00) 
9 (1.20) 
4 (0.53) 
2 (0.27) 
19 (2.53) 
85 (11.33) 
0.0001 
TMP-SMX prophylaxis (n=551) 
Yes 
No 
 
106 (24.31)  
330 (75.69) 
 
45 (39.13)  
70 (60.87) 
0.000 
Prior antibiotic treatment (n=527) 
Yes 
No 
 
69 (16.59) 
347 (83.41) 
 
35 (31.53) 
76 (68.47) 
0.000 
HIV status (n=613) 
Negative 
Positive 
 
53 (11.06) 
426 (88.94) 
 
6 (4.48) 
128 (95.52) 
0.022 
Site of infection (n=3195) 
Invasive  
Non-invasive 
 
1252 (51.21) 
1193 (48.79) 
 
274 (36.53) 
476 (63.47) 
0.000 
Other immune compromise (n=416) 
TB 
Chronic disease 
Other immune suppression 
None 
 
164 (51.57) 
16 (5.03) 
93 (29.25) 
45 (14.15) 
 
63 (64.29) 
1 (1.02) 
19 (19.39) 
15 (15.31) 
0.0462 
Resistant to TMP-SMX (n=3195) 
Yes 
No 
 
1028 (42.04) 
1417 (57.96) 
 
741 (98.80) 
9 (1.20) 
0.000 
ESBL-producer (n=3195) 
Yes 
No 
 
346 (14.15) 
2099 (85.85) 
 
548 (73.07) 
202 (26.93) 
0.000 
Serotype (n=3195)   0.0001 
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Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
1265 (51.74) 
322 (13.17) 
207 (8.47) 
172 (7.03) 
90 (3.68) 
389 (15.91) 
324 (43.20) 
382 (50.93) 
0 
29 (3.87) 
0 
15 (2.00) 
1 Stata could not calculate Fisher’s exact p value because of memory requirements 
2 Fisher’s exact p value 
3.7.5 Relationship between ≥1 MDR pattern and prophylactic use of TMP-SMX 
A summary of results from the univariate analysis of isolates with at least one MDR 
pattern with each risk factor in turn is presented in Table 3.9.  
3.7.5.1 Demographic factors 
 Age and province of origin of isolate were significantly associated with at least one 
MDR pattern (χ² p≤0.05). 
3.7.5.2 Clinical factors 
 Chi-squared tests show that being on TMP-SMX prophylaxis, prior antibiotic 
treatment and site of infection were all significantly associated with at least one of the 
four identified MDR patterns (χ² p≤0.05). 
3.7.5.3 Microbiological factors 
 TMP-SMX resistance, ESBL-production and serotype were significantly associated 
with at having at least one of the four MDR patterns (χ² p≤0.05).  
Table 3.9: Characteristics of cases and controls with more than one MDR pattern 
 Controls n (%) Cases n (%) p value 
Mean age 24.62 (23.81-25.43) 11.52 (10.58-12.45) 0.0000 
Age group (n=3930) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
 
467 (18.52) 
337 (13.37) 
170 (6.74) 
186 (7.38) 
516 (20.47) 
443 (17.57) 
216 (8.57) 
105 (4.17) 
81 (3.21) 
 
647 (45.92) 
298 (21.15) 
65 (4.61) 
44 (3.12) 
151 (10.72) 
110 (7.81) 
47 (3.34) 
32 (2.27) 
15 (1.06) 
0.000 
Sex (n=3917) 
Female 
Male 
 
1252 (49.70) 
1267 (50.30) 
 
682 (48.78) 
716 (51.22) 
0.582 
Province (n=4265) 
Eastern Cape 
Free State 
 
203 (7.50) 
84 (3.10) 
 
214 (13.74) 
40 (2.57) 
0.0001 
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Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
1376 (50.81) 
369 (13.63) 
51 (1.88) 
158 (5.83) 
9 (0.33) 
67 (2.47) 
391 (14.44) 
743 (47.72) 
207 (13.29) 
16 (1.03) 
11 (0.71) 
2 (0.13) 
34 (2.18) 
290 (18.63) 
TMP-SMX prophylaxis (n=772) 
Yes  
No 
 
146 (26.16) 
412 (73.84) 
 
72 (33.64) 
142 (66.36) 
0.039 
Prior antibiotic treatment 
(n=742) 
Yes 
No 
 
 
101 (18.95) 
432 (81.05) 
 
 
59 (28.23) 
150 (71.77) 
0.006 
HIV status (n=827) 
Negative 
Positive 
 
55 (9.24) 
540 (90.76) 
 
22 (9.48) 
210 (90.52) 
0.915 
Site of infection (n=4265) 
Invasive  
Non-invasive 
 
1554 (57.39) 
1154 (42.61) 
 
493 (31.66) 
1064 (68.34) 
0.000 
Other immune compromise 
(n=501) 
TB 
Chronic disease 
Other immune suppression 
None 
 
 
204 (57.14) 
21 (5.88) 
88 (24.65) 
44 (12.32) 
 
 
90 (62.50) 
4 (2.78) 
32 (22.22) 
18 (12.50) 
0.4532 
Resistant to TMP-SMX (n=4265)
Yes 
No 
 
891 (32.90) 
1817 (67.10) 
 
1485 (95.38) 
72 (4.62) 
0.000 
ESBL-producer (n=4265) 
Yes 
No 
 
140 (5.17) 
2568 (94.83) 
 
1177 (75.59) 
380 (24.41) 
0.000 
Serotype (n=4265) 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
 
1604 (59.23) 
57 (2.10) 
259 (9.56) 
160 (5.91) 
127 (4.69) 
501 (18.50) 
 
492 (31.60) 
966 (62.04) 
14 (0.90) 
42 (2.70) 
0 
43 (2.76) 
0.0001 
1 Stata could not calculate Fisher’s exact p value because of memory requirements 
2 Fisher’s exact p value 
3.8 Multivariate analyses and adjustments for possible confounders / effect 
modifiers 
3.8.1 Unadjusted odds ratios 
Case-control analyses showed that isolates with the ACKSSuT and AKSSuT MDR 
patterns had significant odds of association with the primary exposure (i.e. patient on 
TMP-SMX prophylaxis). Table 3.10 shows the unadjusted odds ratios yielded by these 
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analyses as 1.91 (95% CI 1.14 – 3.19) and 2.00 (1.20 – 3.15) for the MDR patterns 
ACKSSuT and AKSSuT respectively.  
This means that isolates from patients who were on TMP-SMX prophylaxis were 1.91 
times more likely to have the MDR pattern ACKSSuT, and 2.00 times more likely to 
exhibit the AKSSuT MDR pattern. Both of these associations had narrow confidence 
intervals and were significant at the 95% level (p= 0.0080 and 0.0015 respectively).  
Although isolates with the ACSSuT and ACSSuTNx resistance patterns were 1.33 and 
1.44 times more likely to have come from patients on TMP-SMX prophylaxis, these 
associations were not statistically significant.  
NTS isolates having at least one MDR pattern were 1.43 (1.00 – 2.04) times more likely to 
have come from patients who were on TMP-SMX prophylaxis as compared to isolates 
without any of the NTS MDR patterns identified, this relationship was statistically 
significant (p=0.0388).  
Table 3.10 Unadjusted odds ratios for the association between MDR NTS and TMP-
SMX prophylaxis 
MDR categories n OR 95% CI χ²  (df) p values 
ACSSuT 772 1.33 0.91 – 1.93 2.45 (1) 0.1176 
ACKSSuT 551 1.91 1.14 – 3.19 7.03 (1) 0.0080 
ACSSuTNx 772 1.44 0.90 – 2.27 2.64 (1) 0.1040 
AKSSuT 551 2.00 1.26 – 3.15 10.04 (1) 0.0015 
>=1 MDR pattern 772 1.43 1.00 – 2.04 4.27 (1) 0.0388 
3.8.2 Stratified analysis 
Mantel-Haenszel pooled estimates of odds ratios for each explanatory variable were 
obtained and the results of these analyses are presented in Tables 3.11 – 3.15. 
3.8.2.1 Mantel-Haenszel analysis of ACSSuT MDR pattern 
The analysis of the association between the ACSSuT MDR pattern and TMP-SMX 
prophylaxis stratified by each explanatory factor is presented in Table 3.11. 
The stratum-specific odds ratios for the association of ACSSuT with TMP-SMX 
prophylaxis use, taking into account age, province, sex, HIV status, ESBL production, site 
of infection, antibiotic use in the preceding two months and TMP-SMX resistance, do not 
differ significantly from each other (tests of homogeneity p>0.05), therefore the pooled 
odds ratios are reported. The ACSSuT MDR pattern is associated with TMP-SMX 
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prophylaxis independent of patient’s age, sex, province of origin, HIV status, other 
immune compromise, whether the patient was on antibiotics in the two months preceding 
admission, whether the isolate was invasive and whether the serotype isolated was an 
ESBL-producer or resistant to TMP-SMX.  
The test of homogeneity for the association between ACSSuT and prophylactic use of 
TMP-SMX controlling for serotype yielded a significant p value (0.0253), meaning that 
there were differences in the odds ratios for this association stratified by each category of 
serotype. Although the stratum-specific odds ratios show that isolates of the S. enterica 
Enteritidis serotype had a much higher odds of 6.88 for the association of ACSSuT with 
TMP-SMX prophylaxis, the association was not statistically significant (95% CI 0.36 – 
130.47). 
Table 3.11: Odds of association of exposure with MDR pattern ACSSUT and 
adjustment for possible confounders (Mantel-Haenszel odds ratios)  
  Pooled OR 
(95% CI) 
p Stratum-specific 
OR (95% CI) 
p (Test for 
homogeneity) 
Unadjusted OR: 1.33 (0.91 –
1.93) 
    
Age group 1.36 (0.94 – 1.98) 0.1035  0.9963 
Province 1.30 (0.90 – 1.86) 0.1583  0.6507 
Sex 1.33 (0.92 – 1.91) 0.1241  0.3553 
HIV status 1.27 (0.87 – 1.85) 0.2192  0.7747 
Antibiotic use in last 2 months 1.11 (0.75 – 1.66) 0.5959  0.7128 
TMP-SMX resistance 1.17 (0.54 – 1.19) 0.2790  0.1027 
ESBL-producing 0.81 (0.48 – 1.35) 0.4138  0.2203 
Other immune compromise 1.25 (0.87 – 1.80) 0.2188  0.2921 
Site of infection 1.33 (0.93 – 1.90) 0.1221  0.6374 
Po
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Serotype 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
1.19 (0.80 – 1.77) 
 
0.3992 
1.09 (0.70 – 1.70) 
1.04 (0.18 – 5.95) 
6.88 (0.36 -130.47) 
0.53 (0.08 – 3.58) 
D* 
NUC** 
0.0253 
 
*D – no cases in stratum 
**NUC – no unexposed cases in stratum 
3.8.2.2 Mantel-Haenszel analysis of ACKSSuT MDR pattern 
The results of the stratified analysis for the association of the ACKSSuT MDR pattern 
with TMP-SMX prophylaxis are presented in Table 3.12.  
The tests of homogeneity for the stratum-specific odds ratios of the association between 
ACKSSuT and TMP-SMX prophylaxis controlling for age, province of origin of isolate, 
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sex, HIV status, ESBL production, site of infection, antibiotic use in the two months 
preceding admission, TMP-SMX resistance and serotype were all non-significant.  
This means that the stratum-specific odds ratios did not differ from each other statistically 
and that these factors did not confound the association between the ACKSSuT MDR 
pattern and TMP-SMX prophylaxis. As a result, the pooled odds ratios for this association 
taking into account each explanatory variable are reported.  
This analysis showed that the MDR pattern ACKSSuT is associated with TMP-SMX 
prophylaxis independent of all demographic, clinical and microbiological explanatory 
factors examined. The pooled odds ratios and the unadjusted odds ratio for the association 
between the ACKSSuT MDR pattern and TMP-SMX prophylaxis stratified by age, 
province, sex, site of infection and serotype do not differ from each other by more than 
10% (10.99% for province and serotype). In addition, the confidence intervals for these 
odds ratios overlap with that of the unadjusted odds ratio, consequently, the pooled odds 
ratios do not differ significantly from the unadjusted odds ratio. 
Table 3.12: Odds of association of exposure with outcome ACKSSUT and adjustment 
for possible confounders (Mantel-Haenszel odds ratios)  
 Pooled OR 
(95% CI) 
p p (Test for 
homogeneity)  
Unadjusted OR: 1.91 (1.14 – 3.19)    
Age group 1.85 (1.13 – 3.05) 0.0135 0.8906 
Province 1.70 (1.04 – 2.77) 0.0330 0.3613 
Sex 1.98 (1.21 – 3.23) 0.0055 0.2208 
HIV status 1.49 (0.91 – 2.44) 0.1140 0.2806 
Antibiotic use in last 2 months 1.32 (0.78 – 2.22) 0.3010 0.4029 
TMP-SMX resistance 1.22 (0.72 – 2.04) 0.4596 0.4950 
ESBL-producing 1.87 (0.98 – 3.58) 0.0545 0.4369 
Other immune compromise 1.59 (0.98 – 2.58) 0.0599 0.0871 
Site of infection 1.92 (1.17 – 3.12) 0.0080 0.4864 Po
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Serotype 1.70 (1.02 – 2.84) 0.0399 0.4163 
3.8.2.3 Mantel-Haenszel analysis of ACSSuTNx MDR pattern 
The analysis of the association between the ACSSuTNx MDR pattern and TMP-SMX 
prophylaxis stratified by other explanatory factors are presented in Table 3.13. The tests of 
homogeneity for the stratum-specific odds ratios of the association between ACSSuTNx 
and TMP-SMX prophylaxis taking into account all explanatory variables except for 
province of origin of isolate were non-significant (p>0.05). This means that the stratum-
specific odds ratios did not differ from each other statistically. As a result, the pooled odds 
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ratios for the association between ACKSSuT and TMP-SMX taking into account these 
explanatory variables are reported.  
The test for homogeneity of stratum-specific odds ratios for this association taking into 
account province of origin of isolate yielded a significant p value of 0.0034. The stratum-
specific odds ratios are reported in this case, as province of origin of isolate is acting as a 
confounder in this association.  
The association between the ACSSuTNx resistance pattern and TMP-SMX prophylaxis 
for isolates from the KwaZulu-Natal province was 9.33 (1.49 – 58.60), this was higher 
than that of other provinces and statistically significant. Although there were differences in 
the stratum-specific odds ratios for other provinces, these were not statistically significant.  
The odds ratio for the relationship between the ACSSuTNx MDR pattern and TMP-SMX 
prophylaxis for isolates from the Eastern Cape province is 0 as there were no isolates with 
the ACSSuTNx resistance pattern from that province for the period of surveillance.  
The Northern Cape and North West provinces of the country did not contribute data to the 
analysis, as there were no isolates with this MDR pattern from patients on TMP-SMX 
prophylaxis in these provinces.  
Table 3.13: Odds of association of exposure with outcome ACSSuTNx and 
adjustment for possible confounders (Mantel-Haenszel odds ratios)  
 Pooled OR 
(95% CI) 
p Stratum-specific 
OR (95% CI) 
p (Test for 
homogeneity) 
Unadjusted OR: 1.44 (0.90 – 2.27)     
Age group 1.47 (0.93 – 2.34) 0.0982  0.7255 
Province 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
1.36 (0.89 – 2.08) 0.1528  
0.00 
5.00 (0.31 – 80.57)
1.31 (0.78 – 2.20) 
9.33 (1.49 – 58.60)
D* 
D* 
NO** 
NO** 
1.72 (0.44 – 6.69) 
0.0050 
Sex 1.44 (0.93 – 2.23) 0.1037  0.4781 
HIV status 1.44 (0.91 – 2.27) 0.1197  0.4169 
Antibiotic use in last 2 months 1.22 (0.75 – 1.99) 0.4282  0.3110 
TMP-SMX resistance 0.90 (0.56 – 1.42) 0.6392  0.4098 
ESBL-producing 0.94 (0.56 – 1.59) 0.8315  0.0654 
Other immune compromise 1.41 (0.90 – 2.20) 0.1338  0.4988 
Site of infection 1.43 (0.92 – 2.22) 0.1112 NCU***  
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Serotype 1.50 (0.85 – 2.63) 0.1573  0.1417 
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*D – dropped as no cases in strata 
**NO – no observations in strata 
***NCU – no non-invasive cases 
3.8.2.4 Mantel-Haenszel analysis of AKSSuT MDR pattern 
The analysis for the association of the AKSSuT MDR pattern and TMP-SMX prophylaxis 
stratified by each explanatory factor is presented in Table 3.14.  
The tests of homogeneity for the stratum-specific odds ratios of the association between 
AKSSuT and TMP-SMX prophylaxis controlling for all other explanatory variables were 
non-significant. This means that the stratum-specific odds ratios did not differ from each 
other statistically, and the explanatory variables did not confound the association between 
the AKSSuT MDR pattern and TMP-SMX prophylaxis. As a result, the pooled odds ratios 
for the association between AKSSuT and TMP-SMX, taking into account each 
explanatory variable, are reported.  
The pooled odds ratios for age, sex, province, ESBL-producer and site of infection do not 
differ from the unadjusted odds ratio by more than 10%, while the pooled odds ratios for 
prior antibiotic use, other immune compromise and serotype do. However, the confidence 
intervals for each of these odds ratios overlap with that of the unadjusted odds ratio, so 
they do not differ statistically. 
Table 3.14: Odds of association of exposure with outcome AKSSuT and adjustment 
for possible confounders (Mantel-Haenszel odds ratios)  
 Pooled OR 
(95% CI) 
p p (Test for 
homogeneity)  
Unadjusted OR: 2.00 (1.26 – 3.15)    
Age group 2.01 (1.28 – 3.15) 0.0019 0.9372 
Province 1.79 (1.16 – 2.78) 0.0082 0.3035 
Sex 2.04 (1.32 – 3.16) 0.0011 0.1893 
HIV status 1.54 (0.99 – 2.41) 0.0560 0.3599 
Antibiotic use in last 2 months 1.64 (1.03 – 2.61) 0.0359 0.3193 
TMP-SMX resistance 1.24 (0.75 – 1.96) 0.3696 0.5122 
ESBL-producer 1.99 (1.17 – 3.38) 0.0092 0.9519 
Other immune compromise 1.74 (1.13 – 2.69) 0.0112 0.0609 
Site of infection 2.00 (1.29 – 3.10) 0.0016 0.4775 Po
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Serotype 1.72 (1.10 – 2.71) 0.0170 0.1851 
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3.8.2.5 Mantel-Haenszel analysis of ≥1 MDR pattern 
The results of the stratified analysis for the association between having at least one MDR 
pattern with TMP-SMX prophylaxis are presented in Table 3.15.  
 
The tests of homogeneity for the stratum-specific odds ratios of the association between 
ACKSSuT and TMP-SMX prophylaxis controlling for age, province of origin of isolate, 
sex, HIV status, ESBL-production, site of infection, antibiotic use in the two months 
preceding admission and TMP-SMX resistance were all non-significant. As a result, the 
pooled odds ratios for the association between ACKSSuT and TMP-SMX taking into 
account these explanatory variables are reported.  
The test of homogeneity of stratum-specific odds ratios for serotype produced a significant 
p value, χ²p=0.0334. These stratum-specific odds ratios are reported in Table 3.17. As with 
the ACSSuT MDR pattern, the association between having at least one MDR pattern and 
TMP-SMX prophylaxis was 6.88 times more likely in S. enterica Enteritidis isolates than 
for other serotypes. This association was not statistically significant, as with the other 
stratum-specific odds ratios for serotype. 
Again, there were no isolates from patients on TMP-SMX prophylaxis from Northern 
Cape and North West provinces, so these categories were excluded from the analysis. 
None of the stratum-specific odds ratios for province were significantly different, though. 
Table 3.15: Odds of association of exposure with outcome ≥1 MDR pattern and 
possible confounders (Mantel-Haenszel odds ratios)   
 Pooled OR (95% 
CI) 
p Stratum-specific 
OR (95% CI) 
p (Test for 
homogeneity) 
Unadjusted OR: 1.43 (1.00 –
2.04) 
    
Age group 1.48 (1.04 – 2.11) 0.0272  0.9622 
Province 1.39 (0.99 – 1.97) 0.0574  0.5506 
Sex 1.43 (1.01 – 2.02) 0.0403  0.6311 
HIV status 1.33 (0.93 – 1.90) 0.1204  0.7645 
Antibiotic use in last 2
months 
1.29 (0.89 – 1.88) 0.1792  0.7559 
TMP-SMX resistance 0.83 (0.57 – 1.22) 0.3376  0.3397 
ESBL-producing 1.04 (0.67 – 1.62) 0.8669  0.2094 
Other immune compromise 1.36 (0.97 – 1.92) 0.0743  0.1558 
Site of infection 1.43 (1.01 – 2.01) 0.0412  0.6253 
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Serotype 
Typhimurium 
Isangi 
Enteritidis 
1.25 (0.86 – 1.82) 0.2331 
1.09 (0.72 – 1.65) 
1.04 (0.18 – 5.95) 
6.88 (0.36 – 130.47)
0.0334 
 45
Species 
Dublin 
Other 
2.00 (0.39 – 10.22) 
D* 
NUC** 
*D – no cases in stratum 
**NUC – no unexposed cases in stratum 
3.9 Regression modeling of the relationship between use of cotrimoxazole 
prophylaxis and the MDR patterns in NTS 
Univariate and multivariate logistic regression of the ACSSuT resistance pattern with each 
risk factor in turn was carried out and the results are presented in Table 3.16. 
3.9.1 Regression modeling of the ACSSuT MDR pattern 
3.9.1.1 Univariate logistic regression – primary association 
In univariate modeling, the ACSSuT pattern was not significantly associated with the 
primary exposure (use of TMP-SMX prophylaxis), having an odds ratio of 1.33 (95% CI 
0.93 – 1.90, p=0.118). 
3.9.1.2 Univariate logistic regression – demographic factors 
 Age: The odds of having the ACSSuT resistance pattern decreased with each category 
increase in age group as compared to the under-1 year age group (reference group).  
 Sex: ACSSuT isolates were less likely to come from women (OR=0.95, 95% CI 0.82 – 
1.08, p=0.417) than from men (reference group, OR=1), although this relationship was 
not statistically significant. 
 Province: Isolates with the ACSSuT resistance pattern were less likely to come from 
provinces other than Eastern Cape (which was the reference group).  
3.9.1.3 Univariate logistic regression – clinical factors 
 Prior treatment with antibiotics: Isolates from patients who had been on antibiotics in 
the two months preceding admission were 1.95 times more likely to have the ACSSuT 
resistance pattern (95% CI 1.33 – 2.86, p=0.001). 
 HIV status: Being HIV-negative was suggestive of a protective effect as it had a lower 
odds of being associated with the ACSSuT resistance pattern (OR=0.81, 95% CI 0.48 
– 1.38, p=0.440) compared to the reference group (HIV positive) with an OR of 1, 
however this association was not statistically significant.  
 Site of infection: Invasive isolates also had a lower odds of association with ACSSuT 
resistance (OR=0.29, 95% CI 0.25 – 0.33) compared to the reference group which was 
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composed of non-invasive isolates, this association was statistically significant 
(p=0.000.).  
3.9.1.4 Univariate logistic regression – microbiological factors 
 Isolates that were already resistant to TMP-SMX were also 35.23 times more likely to 
have the ACSSuT resistance pattern (95% CI 27.42 – 45.27, p=0.0000).  
 ESBL-producing isolates were much more likely to have the ACSSuT resistance 
pattern, with an odds ratio of 75.99 (95% CI 60.76 – 92.55) compared to those isolates 
that were not ESBL-producers.  
 S. enterica Isangi isolates were 70 times more likely to have the ACSSuT resistance 
pattern than the reference group of S. enterica Typhimurium isolates (OR 70.36, 95% 
CI 52.93 – 93.54). S. enterica Enteritidis isolates were less likely to have the ACSSuT 
resistance pattern compared to the reference group (OR 0.23, 95% CI 0.13 – 0.40, 
p=0.000). It is important to note that all S. enterica Dublin isolates had the outcome, 
i.e. were ACSSuT resistant.  
3.9.1.5 Multivariate regression modeling of the ACSSuT MDR pattern 
The outcome of interest and primary explanatory variable were put into a model with 
those variables that were significant at the 90% level in univariate modeling, namely age, 
province of origin of isolate, site of infection, antibiotic use in the two months preceding 
admission, ESBL production, resistance to TMP-SMX and serotype.  
In multivariate modeling, TMP-SMX prophylaxis was not significantly associated with the 
ACSSuT resistance pattern, after controlling for the effects of demographic, clinical and 
microbiological factors.  
ESBL production, TMP-SMX resistance and serotype were significantly associated with 
the MDR pattern ACSSuT after controlling for the effects of all other variables in the 
model: 
 Isolates which were ESBL-producers were 28.34 (15.43 – 52.05, p=0.000) times more 
likely to have the ACSSuT MDR pattern than those that were not ESBL-producers 
 Patients with NTS isolates resistant to TMP-SMX were 2.47 (1.22 – 4.97, p=0.012) 
times more likely to have the ACSSuT MDR pattern than those that were susceptible 
to TMP-SMX 
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 S. enterica Isangi isolates were 9.58 (3.43 – 26.82, p=0.000) times more likely to have 
the ACSSuT pattern than S. enterica Typhimurium, while S. enterica Species isolates 
were 3.20 (1.13 – 9.08, p=0.029) times more likely to have the ACSSuT MDR pattern. 
Observations for S. enterica Dublin isolates were dropped from the analysis as all of 
these isolates experienced the outcome. All other serotypes were 0.24 (0.06 – 1.02, 
p=0.052) times less likely to have the ACSSuT MDR pattern than S. enterica 
Typhimurium isolates. 
Table 3.16 Univariate and multivariate regression models of ACSSuT MDR pattern 
 Univariate model Multivariate model 
Explanatory var n OR 95% CI p  N OR 95% CI p 
TMP-SMX use 
No 
Yes 
772  
1.00 
1.33 
 
Reference 
0.93 – 1.90 
 
 
0.118 
650  
1.00 
0.68 
 
Reference 
0.38 – 1.24 
 
 
0.207 
Age (grouped) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
3930  
1.00 
0.65 
0.26 
0.14 
0.18 
0.16 
0.12 
0.15 
0.13 
 
Reference 
0.53 – 0.79 
0.20 – 0.36 
0.09 – 0.20 
0.14 – 0.22 
0.12 – 0.20 
0.08 – 0.17 
0.09 – 0.24 
0.07 – 0.23 
 
 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
    
Province 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
4265  
1.00 
0.46 
0.44 
0.46 
0.26 
0.05 
0.21 
0.47 
0.70 
 
Reference  
0.30 – 0.70 
0.36 – 0.55 
0.36 – 0.60 
0.14 – 0.47 
0.03 – 0.11 
0.05 – 1.01 
0.30 – 0.74 
0.55 – 0.90 
 
 
0.000 
0.000 
0.000 
0.000 
0.000 
0.051 
0.001 
0.005 
    
Sex 
Male 
Female 
3917  
1.00 
0.95 
 
Reference 
0.82 – 1.08 
 
 
0.417 
  
NI** 
 
 
 
HIV status 
Yes 
No 
 
 
827 
 
1.00 
0.81 
 
Reference 
0.48 – 1.38 
 
 
0.440 
  
NI** 
  
Antibiotic use in 
last 2 months 
No 
Yes 
 
742 
 
 
1.00 
1.95 
 
 
Reference 
1.33 – 2.86 
 
 
 
0.001 
    
TMP-SMX 
resistance 
No 
Yes 
 
 
 
4265 
 
 
1.00 
35.23 
 
 
Reference 
27.42 – 45.27
 
 
 
0.000 
650  
 
1.00 
2.47 
 
 
Reference 
1.22 – 4.97 
 
 
 
0.012 
ESBL-producer 
No 
 
 
 
1.00 
 
Reference 
 
 
650  
1.00 
 
Reference 
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Yes 4265 75.99 60.76 – 92.55 0.000 28.34 15.43 – 52.05 0.000 
Other immune
compromise 
None  
TB 
Chronic disease 
Other immune
suppression 
 
501 
 
 
 
 
 
 
 
1.00 
1.20 
0.47 
 
0.86 
 
 
Reference 
0.62 – 2.29 
0.12 – 1.79 
 
0.41 – 1.80 
 
 
 
0.591 
0.268 
 
0.685 
  
 
NI** 
  
Invasive NTS 
No 
Yes 
4265  
1.00 
0.29 
 
Reference 
0.25 – 0.33 
 
 
0.000 
    
Serotype 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
4138  
1.00 
70.36 
0.23 
0.81 
D*** 
0.36 
 
 
52.93 – 93.54
0.13 – 0.40 
0.55 – 1.20 
- 
0.26 – 0.50 
 
 
0.000 
0.000 
0.295 
- 
0.000 
650  
1.00 
9.58 
0.41 
3.20 
D*** 
0.24 
 
Reference 
3.43 – 26.82 
0.08 – 1.99 
1.13 – 9.08 
- 
0.06 – 1.02 
 
 
0.000 
0.266 
0.029 
- 
0.052 
*C – collinear – category excluded from analysis 
**NI – factor not significant in stratified analysis / univariate modeling – not included in  
***D – dropped because cases with this serotype 
3.9.2 Univariate regression modeling of the ACKSSuT MDR pattern 
Univariate and multivariate logistic regression of the ACKSSuT resistance pattern with 
each risk factor in turn was carried out and the results are presented in Table 3.17. 
3.9.2.1 Univariate logistic regression – primary association 
In univariate modeling, the ACKSSuT pattern was significantly associated with the 
primary exposure (use of TMP-SMX prophylaxis) having an odds ratio of 1.93 (95% CI 
1.18 – 3.11, p=0.009).  
3.9.2.2 Univariate logistic regression – demographic factors 
 Age: The odds of having the ACKSSuT resistance pattern decreased with increasing 
age as compared to the reference group, i.e. the under-1 year age group (p=0.0000).  
 Sex: Isolates with the ACKSSuT MDR pattern were less likely to come from women 
(OR=0.95, 95% CI 0.79 – 1.13, p=0.556) than from men (OR=1) though this was not 
statistically significant. 
 Isolates with the ACKSSuT resistance pattern were significantly (p=0.0000) less likely 
to come from provinces other than Eastern Cape (which was the reference group)  
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3.9.2.3 Univariate logistic regression – clinical factors 
 Prior antibiotic treatment: Isolates from patients who had been on antibiotics in the two 
months preceding admission were 3.24 times more likely to have the ACKSSuT 
resistance pattern (95% CI 1.94 – 5.42, p=0.000). 
 HIV status: Isolates from HIV positive patients were 2.18 times more likely to have 
the ACKSSuT resistance pattern, however this association was not statistically 
significant (95% CI 0.85 – 5.60, p=0.105) compared to the reference group (isolates 
from HIV negative patients).  
 Site of infection: Invasive isolates also had a lower odds of association with ACKSSuT 
resistance (OR=0.39, 95% CI 0.32 – 0.47) compared to the reference group, which was 
composed of non-invasive isolates; this association was statistically significant 
(p=0.000.).  
3.9.2.4 Univariate logistic regression – microbiological factors 
 TMP-SMX resistance: Isolates that were already resistant to TMP-SMX were also 
98.52 times more likely to have the ACKSSuT resistance pattern, this was significant 
even though the confidence interval for this association was very wide (95% CI 48.85 
– 198.72, p=0.000).  
 ESBL-producers: These isolates were 33.07 times more likely to have the ACKSSuT 
resistance pattern, compared to those isolates that were not ESBL-producers (95% CI 
26.01 – 42.05, p=0.000).  
 Serotype: S. enterica Isangi isolates were 7.04 times more likely to have the 
ACKSSuT resistance pattern than the reference group of S. enterica Typhimurium 
isolates (95% CI 5.74 – 8.63, p=0.000). S. enterica Enteritidis and Dublin isolates all 
experienced the outcome of interest (i.e. had the ACKSSuT resistance pattern). All 
other serotypes were 0.22 times less likely to have the ACKSSuT MDR pattern than S. 
enterica Typhimurium isolates. 
3.9.2.5 Multivariate regression modeling of the ACKSSuT MDR pattern 
The outcome of interest and primary explanatory variable were put into a model with 
those variables that were significant at the 90% level in univariate modeling, namely age, 
province of origin of isolate, site of infection, antibiotic use in the two months preceding 
admission, ESBL production, resistance to TMP-SMX and serotype. Controlling for these 
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variables, the ACKSSuT MDR pattern was not significantly associated with TMP-SMX 
prophylaxis.  
The following explanatory variables were significantly associated with the ACKSSuT 
MDR pattern controlling for all other variables in the model: 
 Isolates from patients who had been on antibiotics in the two months preceding 
admission were 2.19 (0.99 – 4.88, p=0.054) times more likely to have the ACKSSuT 
MDR pattern. 
 Isolates which were ESBL-producers were 17.78 (8.80 – 35.95, p=0.000) times more 
likely to have the ACKSSuT MDR pattern than those that were not ESBL-producers 
 Patients with NTS isolates resistant to TMP-SMX were 7.91 (1.77 – 35.25, p=0.007) 
times more likely to have the ACKSSuT MDR pattern than those that were susceptible 
to TMP-SMX 
Table 3.17 Univariate and multivariate regression models of ACKSSuT MDR 
pattern 
 Univariate model Multivariate model 
Explanatory variable n OR 95% CI p  n OR 95% CI p 
TMP-SMX use 
No 
Yes 
551  
1.00 
1.91 
 
Reference 
1.18 – 3.11 
 
 
0.009 
388  
1.00 
1.32 
 
Reference 
0.61 – 2.86 
0.489 
Age (grouped) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
3195  
1.00 
0.78 
0.39 
0.18 
0.31 
0.29 
0.20 
0.17 
0.23 
 
Reference 
0.61 – 0.99 
0.26 – 0.60 
0.10 – 0.32 
0.23 – 0.42 
0.21 – 0.41 
0.12 – 0.33 
0.08 – 0.35 
0.11 – 0.49 
 
 
0.042 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
    
Province 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
3195  
1.00 
0.33 
0.45 
0.51 
0.23 
0.03 
0.47 
0.57 
0.42 
 
Reference 
0.18 – 0.61 
0.34 – 0.58 
0.37 – 0.69 
0.10 – 0.51 
0.01 – 0.11 
0.10 – 2.25 
0.32 – 1.02 
0.30 – 0.59 
 
 
0.000 
0.000 
0.000 
0.000 
0.000 
0.343 
0.057 
0.000 
    
Sex 
Male 
Female 
3103  
1.00 
0.95 
 
 
0.79 – 1.13 
 
 
0.550 
  
NI*** 
 
  
HIV status 
No 
613  
1.00 
 
Reference 
 
 
  
NI*** 
  
 51
Yes 2.18 0.85 – 5.60 0.105 
Antibiotic use in last 
2 months 
No 
Yes 
 
527 
 
 
1.00 
3.24 
 
 
Reference 
1.94 – 5.42 
 
 
 
0.000 
388  
 
1.00 
2.19 
 
 
Reference 
0.99 – 4.88 
 
 
 
0.054 
TMP-SMX resistance 
No 
Yes 
3195  
1.00 
98.52 
 
Reference 
48.85– 198.72
 
 
0.000 
388  
1.00 
7.91 
 
Reference 
1.77 – 35.25 
 
 
0.007 
ESBL-producer 
No 
Yes 
3195  
1.00 
33.07 
 
Reference 
26.01 – 42.05 
 
 
0.000 
388  
1.00 
17.78 
 
 
8.80 – 35.95 
 
 
0.000 
Other immune
compromise 
None  
TB 
Chronic disease 
Other immune
suppression 
 
399 
 
 
1.00 
1.23 
D* 
0.49 
 
 
Reference 
0.59 – 2.54 
- 
0.20 – 1.20 
 
 
 
0.582 
- 
0.116 
  
 
NI*** 
  
Invasive NTS 
No 
Yes 
3195  
1.00 
0.39 
 
Reference 
0.32 – 0.47 
 
 
0.000 
  
****NUC 
  
Serotype 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
2898  
1.00 
7.04 
D* 
0.63 
D* 
0.22 
 
 
5.74 – 8.63 
- 
0.38 – 1.03 
- 
0.12 – 0.37 
 
 
0.000 
- 
0.063 
- 
0.000 
    
*D – dropped because no cases in these strata 
**C – dropped because of collinearity 
***NI – not included in model 
****NUC- no unexposed cases 
3.9.3 Univariate and multivariate regression modeling of the ACSSuTNx MDR 
pattern 
Univariate and multivariate logistic regression of the ACSSuTNx resistance pattern with 
each risk factor in turn was carried out and the results are presented in Table 3.18. 
3.9.3.1 Univariate logistic regression – primary association 
In univariate modeling, the ACSSuTNx MDR pattern was not significantly associated 
with the primary exposure (use of TMP-SMX prophylaxis) having an odds ratio of 1.44 
(95% CI 0.93 – 2.23, p=0.105).  
3.9.3.2 Univariate logistic regression – demographic factors 
 Age: The odds of having the ACSSuTNx resistance pattern decreased with increasing 
age as compared to the reference group (under 1 year age group, p=0.0000).  
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 Sex: Isolates with This MDR pattern were less likely to come from women (OR=0.94, 
95% CI 0.82 – 1.09,) than from men (OR=1), although the latter was not statistically 
significant (p=0.423). 
 Province: Isolates with the ACSSuTNx resistance pattern were significantly 
(p=0.0000) less likely to come from provinces other than Eastern Cape (which was the 
reference group) 
3.9.3.3 Univariate logistic regression – clinical factors 
 Prior antibiotic treatment: Isolates from patients who had been on antibiotics in the two 
months preceding admission were 1.79 times more likely to have the ACSSuTNx 
resistance pattern (95% CI 1.12 – 2.85, p=0.000). 
 HIV status: Isolates from HIV positive patients were 0.71 times less likely to have the 
ACSSuTNx resistance pattern, however this association was not statistically 
significant (95% CI 0.38 – 1.31, p=0.277) compared to the reference group (HIV 
negative).  
 Site of infection: Invasive isolates also had a lower odds of association with 
ACSSuTNx resistance (OR=0.21, 95% CI 0.18 – 0.25) compared to the reference 
group, which was composed of non-invasive isolates; this association was statistically 
significant (p=0.000). 
3.9.3.4 Univariate logistic regression – microbiological factors 
 TMP-SMX resistance: Isolates that were already resistant to TMP-SMX were also 
56.04 times more likely to have the ACSSuTNx resistance pattern, this was significant 
even though the confidence interval for this association was very wide (95% CI 38.26 
– 82.11, p=0.000).  
 ESBL-producers: These isolates were 43.66 times more likely to have the ACSSuTNx 
resistance pattern, compared to those isolates that were not ESBL-producers (95% CI 
35.82 – 53.22, p=0.000).  
 Serotype: S. enterica Isangi isolates were 76.84 times more likely to have the 
ACSSuTNx resistance pattern than the reference group of S. enterica Typhimurium 
isolates (95% CI 60.37 – 97.80, p=0.000). S. enterica Dublin isolates did not 
experience the outcome of interest (i.e. did not have the ACSSuTNx resistance 
pattern). All other serotypes were 0.51 times as likely to have the ACSSuTNx MDR 
pattern than S. enterica Typhimurium isolates (p=0.003). 
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3.9.3.5 Multivariate regression modeling of the ACSSuTNx MDR pattern 
The outcome of interest and primary explanatory variable (use of TMP-SMX prophylaxis) 
were put into a model with those variables that were significant at the 90% level in 
univariate modeling, namely age, province of origin of isolate, site of infection, antibiotic 
use in the two months preceding admission, ESBL production, resistance to TMP-SMX 
and serotype. Controlling for these variables, the ACSSuTNx MDR pattern was not 
significantly associated with TMP-SMX prophylaxis (OR=0.83, 0.39 – 1.74, p=0.617).  
The following explanatory variables were significantly associated with the relationship 
between the ACSSuTNx MDR pattern controlling for all other variables in the 
multivariate model: 
 Isolates that were ESBL-producers were 32.31 (14.19 – 73.55, p=0.000) times more 
likely to have the ACSSuTNx MDR pattern 
 S. enterica Isangi isolates from patients on TMP-SMX prophylaxis were 49.54 (18.72 
– 171.53, p=0.000) times more likely to have the ACKSSuT MDR pattern  
 NTS isolates serotyped as S. enterica Species from patients on TMP-SMX prophylaxis 
were 7.44 times more likely to have the ACSSuTNx MDR pattern (1.79 – 30.80, 
p=0.006) than S. enterica Typhimurium isolates 
Table 3.18 Univariate and multivariate regression model of ACSSuTNx MDR 
pattern 
 Univariate model Multivariate model 
Explanatory variable n OR 95% CI p  n OR 95% CI p 
TMP-SMX use 
No 
Yes 
772  
1.00 
1.44 
 
Reference 
0.93 – 2.23 
 
 
0.105 
515 
 
 
1.00 
0.83 
 
Reference 
0.39 – 1.74 
 
 
0.617 
Age (grouped) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
3930  
1.00 
0.70 
0.28 
0.10 
0.15 
0.12 
0.08 
0.14 
0.13 
 
Reference 
0.58 – 0.86 
0.20 – 0.40 
0.06 – 0.17 
0.11 – 0.19 
0.09 – 0.16 
0.05 – 0.14 
0.08 – 0.25 
0.07 – 0.26 
 
 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
    
Sex 
Male 
Female 
3917  
1.00 
0.94 
 
Reference 
0.82 – 1.09 
 
 
0.423 
  
NI*** 
  
Province 
Eastern Cape 
Free State 
Gauteng 
4265  
1.00 
0.73 
0.48 
 
Reference 
0.47 – 1.11 
0.38 – 0.60 
 
 
0.148 
0.000 
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KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
0.67 
0.03 
0.02 
0.17 
0.50 
1.12 
0.51 – 0.87 
0 – 0.19 
0.01- 0.08 
0.02 – 1.35 
0.30 – 0.84 
0.87 – 1.44 
0.003 
0.000 
0.000 
0.093 
0.008 
0.370 
Antibiotic use in last 
2 months 
No 
Yes 
 
742 
 
 
1.00 
1.79 
 
 
Reference 
1.12 – 2.85 
 
 
 
0.015 
    
HIV status 
No  
Yes 
827  
1.00 
0.71 
 
Reference 
0.38 – 1.31 
 
 
0.277 
  
NI*** 
  
Other immune
compromise 
None  
TB 
Chronic disease 
Other immune
suppression 
 
476 
 
 
1.00 
0.66 
D* 
 
0.74 
 
 
Reference 
0.32 – 1.34 
- 
 
0.33 – 1.64 
 
 
 
0.247 
- 
 
0.454 
 NI***  
 
 
 
Invasive NTS 
No 
Yes 
4265  
1.00 
0.21 
 
Reference 
0.18 – 0.25 
 
 
0.000 
  
****NUC 
  
TMP-SMX 
resistance 
No 
Yes 
4265  
 
1.00 
56.04
 
 
Reference 
38.26 – 82.11
 
 
 
0.000 
    
ESBL-producer 
No 
Yes 
4265  
1.00 
43.66
 
Reference 
35.82 – 53.22
 
 
0.000 
515  
1.00 
32.31 
 
Reference 
14.19 – 73.55 
 
 
0.000 
Serotype 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
4138  
1.00 
76.84 
0.08 
1.51 
D* 
0.51 
 
Reference 
60.37 – 97.80
0.02 – 0.33 
0.96 – 2.37 
- 
0.33 – 0.80 
 
 
0.000 
0.000 
0.076 
- 
0.003 
515  
1.00 
56.66 
D* 
7.44 
D* 
0.68 
 
Reference 
18.72 – 171.53
- 
1.79 – 30.80 
- 
0.18 –  4.93 
 
 
0.000 
- 
0.006 
- 
0.948 
*D – dropped as no cases in strata 
**C – dropped because of collinearity 
***NI – not included in model 
****NUC – no unexposed cases 
3.9.4 Univariate and multivariate regression modeling of the AKSSuT MDR 
pattern 
Univariate and multivariate logistic regression of the AKSSuT resistance pattern with each 
risk factor in turn was carried out and the results are presented in Table 3.18. 
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3.9.4.1 Univariate logistic regression – primary association 
In univariate modeling, the AKSSuT MDR pattern was very significantly associated with 
the primary exposure (use of TMP-SMX prophylaxis) having an odds ratio of 2.00 (95% 
CI 1.30 – 3.09, p=0.002).  
3.9.4.2 Univariate logistic regression – demographic factors 
 Age: The odds of having the AKSSuT resistance pattern decreased with increasing age 
as compared to the reference group (under 1 year age group, p=0.0000).  
 Sex: Isolates with this MDR pattern were less likely to come from women (OR=0.98, 
95% CI 0.83 – 1.16) than from men (OR=1), although the latter was not statistically 
significant (p=0.836). 
 Province: Isolates with the AKSSuT resistance pattern were significantly (p=0.0000) 
less likely to come from provinces other than Eastern Cape (which was the reference 
group)  
3.9.4.3 Univariate logistic regression – clinical factors 
 Prior antibiotic treatment: Isolates from patients who had been on antibiotics in the two 
months preceding admission were 2.32 times more likely to have the AKSSuT 
resistance pattern (95% CI 1.44 – 3.73, p=0.001). 
 HIV status: Isolates from HIV positive patients were 2.65 times more likely to have 
the AKSSuT resistance pattern, this association was statistically significant (95% CI 
1.12 – 6.22, p=0.027) compared to the reference group (isolates from HIV negative 
patients).  
 Site of infection: Invasive isolates also had a lower odds of association with AKSSuT 
resistance (OR=0.55, 95% CI 0.46 – 0.65) compared to the reference group, which was 
composed of non-invasive isolates; this association was statistically significant 
(p=0.000).  
3.9.4.4 Univariate logistic regression – microbiological factors 
 TMP-SMX resistance: Isolates that were already resistant to TMP-SMX were also 
113.49 times more likely to have the AKSSuT resistance pattern, this was statistically 
significant (95% CI 58.54 – 220.03, p=0.000).  
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 ESBL-producers: These isolates were 16.46 times more likely to have the AKSSuT 
resistance pattern, compared to those isolates that were not ESBL-producers (95% CI 
13.51 – 20.05, p=0.000).  
 Serotype: S. enterica Isangi isolates were 4.63 times more likely to have the AKSSuT 
resistance pattern than the reference group of S. enterica Typhimurium isolates (95% 
CI 3.82 – 5.61, p=0.000). S. enterica Dublin and Enteritidis isolates all experienced 
the outcome of interest (i.e. had the AKSSuT resistance pattern and were excluded 
from the model). Serotypes grouped as S. enterica Species were 0.66 times less likely 
to have the AKSSuT MDR pattern (0.44 – 0.99, p=0.047). All other serotypes were 
0.15 times less likely to have the AKSSuT MDR pattern than S. enterica 
Typhimurium isolates (0.09 – 0.26, p=0.000). 
3.9.4.5 Multivariate regression modeling of the AKSSuT MDR pattern 
The outcome of interest and primary explanatory variable (use of TMP-SMX prophylaxis) 
were put into a model with those variables that were significant at the 90% level in 
univariate modeling, namely age, province of origin of isolate, HIV status, site of 
infection, antibiotic use in the two months preceding admission, ESBL production, 
resistance to TMP-SMX and serotype. After controlling for these variables, TMP-SMX 
prophylaxis was not significantly associated with the AKSSuT MDR pattern (OR=0.92, 
0.50 – 1.70, p=0.802). The following were significantly associated with the relationship 
between the AKSSuT MDR pattern after controlling for the effects of all other variables in 
the model: 
 Isolates that were ESBL-producers were 10.72 (5.60 – 20.52, p=0.000) times more 
likely to have the AKSSuT MDR pattern 
 Isolates from HIV positive patients were 5.89 times more likely to have the AKSSuT 
MDR pattern; this association was statistically significant (p=0.000) even though the 
confidence interval around the odds ratio was quite wide (1.61 – 21.60) 
 Isolates that were TMP-SMX resistant were 16.90 times more likely to have the 
AKSSuT MDR pattern (3.95 – 72.26, p=0.000) 
Table 3.19 Univariate and multivariate regression model of AKSSuT MDR pattern 
 Univariate model Multivariate model 
Explanatory variable n OR 95% CI p  n OR 95% CI p 
TMP-SMX use 
No 
Yes 
551  
1.00 
2.00 
 
Reference 
1.30 – 3.09 
 
 
0.002 
364  
1.00 
0.92 
 
Reference 
0.50 – 1.70 
 
 
0.802 
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Age (grouped) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
3028  
1.00 
0.76 
0.43 
0.29 
0.42 
0.37 
0.32 
0.39 
0.24 
 
Reference 
0.60 – 0.97 
0.29 – 0.64 
0.18 – 0.46 
0.32 – 0.55 
0.27 – 0.49 
0.21 – 0.49 
0.23 – 0.66 
0.12 – 0.49 
 
 
0.018 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
    
Sex 
Male 
Female 
3103  
1.00 
0.98 
 
Reference 
0.83 – 1.16 
 
 
0.836 
  
NI*** 
  
Province 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
3195  
1.00 
0.32 
0.59 
0.62 
0.29 
0.05 
0.46 
0.60 
0.43 
 
Reference 
0.18 – 0.60 
0.46 – 0.77 
0.46 – 0.83 
0.14 – 0.61 
0.02 – 0.14 
0.10 – 2.19 
0.34 – 1.05 
0.31 – 0.59 
 
 
0.000 
0.000 
0.002 
0.001 
0.000 
0.326 
0.075 
0.000 
    
Antibiotic use in last 
2 months 
No 
Yes 
 
527 
 
 
1.00 
2.32 
 
 
Reference 
1.44 – 3.73 
 
 
 
0.001 
    
HIV status 
No  
Yes 
613  
1.00 
2.65 
 
Reference 
1.12 – 6.32 
 
 
0.027 
364  
1.00 
5.89 
 
Reference 
1.61 – 21.60 
 
 
0.007 
Other immune
compromise 
None  
TB 
Chronic disease 
Other immune
suppression 
 
416 
 
 
1.00 
1.15 
0.19 
0.61 
 
 
Reference 
0.60 – 2.21 
0.02 – 1.54 
0.29 – 1.32 
 
 
 
0.119 
0.670 
0.210 
  
 
NI*** 
  
Invasive NTS 
No 
Yes 
3195  
1.00 
0.55 
 
Reference 
0.46 – 0.65 
 
 
0.000 
 364 
1.00 
1.05 
 
Reference 
0.4 – 29.17 
 
 
0.977 
TMP-SMX 
resistance 
No 
Yes 
3195  
 
1.00 
113.49
 
 
Reference 
58.54– 220.03
 
 
 
0.000 
364  
 
1.00 
16.90 
 
 
Reference 
3.95 – 72.26 
 
 
 
0.000 
ESBL-producer 
No 
Yes 
3195  
1.00 
16.46 
 
Reference 
13.51 – 20.05 
 
 
0.000 
364  
1.00 
10.72 
 
Reference 
5.60 – 20.52 
 
 
0.000 
Serotype 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
2898  
1.00 
4.63 
D* 
0.66 
D* 
0.15 
 
Reference 
3.82 – 5.61 
- 
0.44 – 0.99 
- 
0.09 – 0.26 
 
 
0.000 
- 
0.047 
- 
0.000 
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*D – dropped as no cases in strata 
**C – dropped because of collinearity 
***NI – not included in model 
3.9.5 Univariate and multivariate regression modeling of  isolates with at least one 
MDR pattern 
3.9.5.1 Univariate logistic regression – primary association 
In univariate modeling, having at least one multi-drug resistance pattern was significantly 
associated with the use of TMP-SMX prophylaxis, having an odds ratio of 1.43 (95% CI 
1.02 – 2.01, p=0.039).  
3.9.5.2 Univariate logistic regression – demographic factors 
 Age: The odds of having at least one MDR pattern decreased significantly with 
increasing age as compared to the reference group (p=0.0000).  
 Sex: Isolates with this MDR pattern were less likely to come from women (OR=0.96, 
95% CI 0.85 – 1.10) than from men (OR=1), although the latter was not statistically 
significant (p=0.582). 
 Province: Isolates with the AKSSuT resistance pattern were significantly (p=0.0000) 
less likely to come from provinces other than Eastern Cape (which was the reference 
group)  
3.9.5.3 Univariate logistic regression – clinical factors 
 Prior antibiotic treatment: Isolates from patients who were treated with antibiotics in 
the two years preceding admission were 1.68 times more likely to have at least one of 
the MDR patterns identified (95% CI 1.16 – 2.44, p=0.006). 
 HIV status: Isolates from HIV positive patients and invasive sites were not 
significantly associated with having at least one MDR pattern,). Other immune 
compromise factors were not significantly associated with having at least one MDR 
pattern.  
 Site of infection: Isolates from invasive sites were less likely to have at least one MDR 
pattern (OR=0.34, 95% CI 0.30 – 0.39) compared to the reference group, which was 
composed of non-invasive isolates; this association was statistically significant 
(p=0.000).  
3.9.5.4 Univariate logistic regression – microbiological factors 
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 TMP-SMX resistance: Isolates that were already resistant to TMP-SMX were also 
42.06 times more likely to have at least one MDR pattern, this was statistically 
significant (95% CI 32.77 – 53.99, p=0.000).  
 ESBL-producers: These isolates were 56.81 times more likely to have at least one 
MDR pattern, compared to those isolates that were not ESBL-producers (95% CI 
46.25 – 69.79, p=0.000).  
 Serotype: S. enterica Isangi isolates were 55.25 times more likely to have at least one 
MDR pattern than the reference group of S. enterica Typhimurium isolates (95% CI 
41.52 – 73.52, p=0.000). S. enterica Enteritidis isolates were 0.18 times less likely to 
have at least one MDR pattern; this association was statistically significant (95% CI 
0.10 – 0.30, p=0.000). All S. enterica Dublin isolates experienced the outcome of 
interest (i.e. had at least one MDR pattern and were excluded from the model). All 
other serotypes were 0.28 times less likely to be associated with any MDR pattern 
(95% CI 0.20 – 0.39, p=0.000). 
3.9.5.5 Multivariate regression modeling of at least one MDR pattern 
The outcome of interest and primary explanatory variable (use of TMP-SMX prophylaxis) 
were put into a model with those variables that were significant at the 90% level in 
univariate modeling, namely age, province of origin of isolate, site of infection, antibiotic 
use in the two months preceding admission, ESBL production, resistance to TMP-SMX 
and serotype. After controlling for these variables, TMP-SMX prophylaxis was not 
significantly associated with having at least one MDR pattern (OR=0.76, 0.44 – 1.31, 
p=0.323). The following were significantly associated with having at least one MDR 
pattern after controlling for the effects of all other variables in the model: 
 TMP-SMX resistant isolates were 4.94 times more likely (95% CI 2.50 – 9.74, 
p=0.000) to have at least one MDR pattern 
 ESBL-producing isolates were 15.62 times more likely to have at least one MDR 
pattern; this association was statistically significant (95% CI 8.58 – 28.42, p=0.000)  
 S. enterica Isangi isolates were 4.32 times more likely to have at least one MDR 
pattern (95% CI 1.43 – 13.08, p=0.010), while isolates serotyped as S. enterica 
Species were 3.58 times more likely to have at least one MDR pattern (95% CI 1.37 – 
9.39, p=0.009) when compared to S. enterica Typhimurium isolates. All other isolates 
were less likely to have at least one MDR pattern (OR=0.15, 95% CI 0.03 – 0.62, 
p=0.009) 
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 Isolates from certain age categories were less likely to have at least one MDR pattern 
than infants less than one year of age  
Table 3.20 Univariate and multivariate regression model of ≥1MDR pattern  
 Univariate model Multivariate model 
Explanatory variable n OR 95% CI p  n OR 95% CI p 
TMP-SMX use 
No 
Yes 
772  
1.00 
1.43 
 
Reference 
1.02 – 2.01 
 
 
0.039
577  
1.00 
0.76 
 
Reference 
0.44 – 1.31 
 
 
0.323 
Age (grouped) 
<1 year 
1-4 years 
5-14 years 
15-24 years 
25-34 years 
35-44 years 
45-54 years 
55-64 years 
>=65 years 
3930 
 
 
1.00 
0.64 
0.28 
0.17 
0.21 
0.18 
0.16 
0.22 
0.13 
 
Reference  
0.52 – 0.78 
0.20 – 0.38 
0.12 – 0.24 
0 17 – 0.26 
0.14 – 0.23 
0.11 – 0.22 
0.15 – 0.33 
0.08 – 0.23 
 
 
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
577  
1.00 
0.34 
0.38 
0.39 
0.40 
0.42 
0.37 
0.95 
 
 
Reference 
0.12 – 0.97 
0.09 – 1.56 
0.12 – 1.26 
0.18 – 0.91 
0.19 – 0.93 
0.13 – 1.06 
0.25 – 3.70 
 
 
 
0.044 
0.181 
0.116 
0.030 
0.033 
0.065 
0.946 
 
Sex 
Male 
Female 
3917  
1.00 
0.96 
 
Reference 
0.85 – 1.10 
 
 
0.582
 NI**   
Province 
Eastern Cape 
Free State 
Gauteng 
KwaZulu-Natal 
Limpopo 
Mpumalanga 
Northern Cape 
North West 
Western Cape 
4265  
1.00 
0.45 
0.51 
0.53 
0.30 
0.07 
0.21 
0.48 
0.70 
 
Reference 
0.30 – 0.69 
0.41 – 0.63 
0.41 – 0.69 
0.16 – 0.54 
0.03 – 0.13 
0.05 – 0.99 
0.31 – 0.76 
0.55 – 0.90 
 
 
0.000
0.000
0.000
0.000
0.000
0.048
0.002
0.005
    
Antibiotic use in last 2 
months 
No 
Yes 
 
742 
 
 
1.00 
1.68 
 
 
Reference 
1.16 – 2.44 
 
 
 
0.006
    
HIV status 
No  
Yes 
827  
1.00 
0.97 
 
Reference 
0.58 – 1.63 
 
 
0.915
  
NI** 
  
Other immune 
compromise 
None  
TB 
Chronic disease 
Other immune 
suppression 
 
501 
 
 
1.00 
1.08 
0.47 
 
0.89 
 
 
Reference 
0.59 – 1.97 
0.14 – 1.55 
 
0.45 – 1.76 
 
 
 
0.806
0.212
 
0.735
    
Invasive NTS 
No 
Yes 
4265  
1.00 
0.34 
 
Reference 
0.30 – 0.39 
 
 
0.000
    
TMP-SMX resistance 
No 
Yes 
4265  
1.00 
42.06 
 
Reference 
32.77– 53.99 
 
 
0.000
577  
1.00 
4.94 
 
Reference 
2.50 – 9.74 
 
 
0.000 
ESBL-producer 4265    577    
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No 
Yes 
 1.00 
56.81 
Reference 
46.25 – 69.79 
 
0.000
1.00 
15.62 
Reference 
8.58 – 28.42 
 
0.000 
Serotype 
Typhimurium 
Isangi 
Enteritidis 
Species 
Dublin 
Other 
4138  
1.00 
55.25 
0.18 
0.86 
NC***
0.28 
 
Reference 
41.52 – 73.52 
0.10 – 0.30 
0.60 – 1.22 
- 
0.20 – 0.39 
 
 
0.000
0.000
0.389
- 
0.000
577  
1.00 
4.32 
- 
3.58 
NC***
0.15 
 
Reference 
1.43 – 13.08 
- 
1.37 – 9.39 
- 
0.03 – 0.62 
 
 
0.010 
- 
0.009 
- 
0.009 
*D – dropped as no cases in strata 
**C – dropped because of collinearity 
***NI – not included in model 
3.10 Relationship between invasive disease and TMP-SMX resistance 
A univariate logistic regression model was fitted to investigate the relationship between 
invasive NTS infection and TMP-SMX resistance. This analysis produced an odds of the 
association between invasive disease and TMP-SMX resistance of 0.87 (95% CI 0.77 – 
0.99, p=0.029), implying that invasive disease is  protective against TMP-SMX resistance.
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4.0 DISCUSSION 
4.1 Annual incidence of NTS 
The annual incidence of invasive NTS was consistent with findings reported previously 
(GERMSSA, 2006). There was insufficient data to assess trends in NTS incidence over 
time as this analysis covered only three year’s of surveillance data. Furthermore, incidence 
was only calculated for invasive isolates as not all non-invasive isolates are detected by 
routine / enhanced surveillance or cultured in practice. 
4.2 Prevalence of NTS serotypes by year and geographically 
S. enterica Typhimurium was the most predominant serotype identified, contributing just 
under 50% of isolates tested during the period of surveillance (i.e. 01/01/2003 – 
31/12/2005). This finding is in keeping with what was reported by Helms and others 
(Helms et al, 2005). Although NTS surveillance data for 2006 has reflected a prevalence 
of S. enterica Typhimurium isolates of 68% (GERMSSA, 2006), analysis for trends over 
time was not carried out because of insufficient data. 
4.3 Prevalence of NTS resistance in South Africa 
A very high proportion, 82.84%, of all isolates tested were resistant to more than one of 
the 15 antibiotics tested. 30.88% of the isolates tested were ESBL-producers, this is in 
keeping with more recent findings in South Africa (GERMSSA, 2006). 76.31% of ESBL-
producing isolates were also resistant to nalidixic acid. This high level of resistance to 
nalidixic acid means that the patients who contributed these isolates would not be able to 
be treated effectively with floroquinolones. This also implies that floroquinolones, often a 
last resort against resistant infections, may no longer be able to be successfully used. The 
majority of the ESBL-producing isolates (44.04%) were received from Gauteng, with the 
Western Cape (20.20%) having the next highest number of ESBL-producing isolates. It 
must be borne in mind that this finding may reflect the fact that access to medical care 
may be easier and public health infrastructure may be better in these provinces. These 
results and the high resistance rates observed from these two provinces, in general, may 
therefore reflect the ease with which cases are detected, as well as higher numbers of NTS 
cases diagnosed and hospital admissions in these provinces. This study also found that, 
between 2003 and 2005, there were high rates of resistance to all antibiotics tested except 
for ciprofloxacin and imipenem. Resistance to imipenem in NTS was not observed as 
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expected in South Africa (personal communication, K Keddy, 2009). The low resistance to 
ciprofloxacin is in keeping with previously observed lack of resistance to this drug 
(Kariuki et al, 2005). This implies that ciprofloxacin may still be effective against NTS. 
Across all provinces, consistently high rates of resistance (>56% of isolates) were 
observed to sulfamethoxazole. This finding is similar to that of Mwansa and co-workers 
(Mwansa et al, 2002) and has implications for the continued use of antibiotics against 
diseases when these levels of resistance exist. 
4.4 Prevalence of MDR patterns 
GERMSSA reported that 50.7% of NTS isolates were penta-resistant, this study found that 
36.51 percent of isolates exhibited at least one of the MDR penta-resistance patterns 
(GERMSSA, 2006). Of the NTS isolates tested, 33.93% exhibited the classic penta-
resistance pattern (ACSSuT), while 20.03%, 26.14% and 23.47% of isolates exhibited 
MDR patterns ACKSSuT, ACSSuTNx and AKSSuT respectively, over the period 2003 to 
2005. The low rates of AKSSuT and ACKSSuT MDR patterns may be attributable to this 
data not being collected prior to 2004. 
The majority of isolates with the MDR patterns came from younger patients with the mean 
age of cases ranging from 8.11 to 13.52 years compared to controls (isolates which did not 
have any of the 4 MDR patterns identified) which ranged in mean age from 21.92 to 24.76 
years. There were no significant differences in the distribution of cases and controls 
between male and female patients, regardless of the MDR pattern exhibited by the isolates. 
4.5 Geographic distribution of MDR NTS 
Although χ² tests showed that there were significant differences in the distribution of cases 
and controls in the provinces from which isolates were obtained (p=0.000), univariate 
modeling of each MDR pattern with province showed significant geographical differences 
only for the MDR pattern ACSSuTNx (OR 5.01 95% CI 1.21 – 20.73; p=0.026) . As the 
confidence interval around this odds ratio is quite wide, some uncertainty exists as to the 
validity of this finding. This finding may also reflect differences between provinces, in 
terms of surveillance systems as well as access to health care, the capacity to detect cases 
accurately (which may be better in provinces with large academic hospitals). As this is the 
first such analysis of South African surveillance data for NTS resistance, it will be of 
interest to see how this compares with data collected in future. 
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4.6 Association between prophylactic TMP-SMX usage and MDR NTS 
This study demonstrated that there are associations between prophylactic usage of 
trimethoprim-sulfamethoxazole (TMP-SMX) and multi-drug resistance (MDR) patterns in 
non-typhoidal salmonellae (NTS) isolates tested as part of a national surveillance 
programme.  
These associations were not significant for the MDR patterns ACSSuT and ACSSuTNx, 
but NTS isolates from patients who had been on prophylactic TMP-SMX were 1.91 times 
more likely to have the ACKSSuT MDR pattern (95% CI 1.14 – 3.19, p=0.0080) and 2.00 
times more likely to have the AKSSuT MDR pattern (95% CI 1.26 – 3.15, p=0.0015). In 
addition, NTS isolates from patients on prophylactic TMP-SMX were 1.43 times more 
likely to have at least one of the four MDR patterns investigated (95% CI 1.00 – 2.04, p = 
0.0388).  
There were no previously published findings against which these observed associations 
could be measured; although the observation and prevalence of these patterns is in keeping 
with what was found by other researchers (Glynn et al, 1998; Helms et al, 2002; Helms et 
al, 2005 and Rabatsky-Ehr et al, 2004). 
In multivariate regression analysis, TMP-SMX prophylaxis was not significantly 
associated with any of the MDR patterns. This could be due to the loss of observations in 
multivariate regression models to account for the large proportion of missing data on key 
factors (e.g. TMP-SMX prophylaxis, prior treatment with antibiotics, other immune 
compromise). 
4.7 Other factors associated with MDR NTS 
4.7.1 Demographic factors 
In univariate logistic regression models, the following factors were significantly associated 
with each MDR pattern:  
 Age: The odds of having either ACSSuT, ACKSSuT, ACSSuTNx, AKSSuT or more 
than one of these MDR patterns decreased with each category increase in age.  
 Province: There was a lower odds of having and MDR pattern if an isolate came from 
a province other than the Eastern Cape. We were unable to compare this to previous 
findings, as there were no studies that have looked at the distribution of MDR NTS 
patterns in NTS in South Africa prior to this. 
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Neither of these factors was significantly associated with TMP-SMX prophylaxis in 
multivariate analysis. 
4.7.2 Clinical factors 
The following factors were significantly associated with TMP-SMX prophylaxis in 
univariate regression modeling: 
 Prior treatment with antibiotics: isolates from patients who had been on antibiotic 
treatment in the two months preceding admission were more likely to have each of the  
MDR patterns – this is in keeping with existing knowledge on the association between 
the use of antibiotics and drug resistance (EMEA, 1999; Glynn et al, 2004; Fisk et al 
2005). 
 Site of infection: Invasive isolates were less likely to have either one or more of these 
MDR patterns – this conflicts with earlier evidence that links invasive disease to 
increased likelihood of drug resistance (Rabatsky-Ehr et al, 2004; Fisk et al, 2005, 
CDC, 2004). It is possible that there may be some underlying interaction between HIV 
status, being on TMP-SMX prophylaxis and invasive disease. 91% of invasive isolates 
were HIV positive, but it was not possible to assess  this because all non-invasive 
isolates were HIVpositive / negative. 
 In addition, HIV status was associated with the AKSSuT MDR pattern. This finding is 
consistent with existing knowledge (Gianella, 1996), although we were unable to 
explain why it was observed only to the AKSSuT MDR pattern, and there is a lack of 
published literature to either support or dispute this finding. 
 In multivariate modeling, prior antibiotic treatment remained significantly associated 
with the ACKSSuT MDR pattern only, while HIV status remained significantly 
associated with the AKSSuT MDR pattern. Site of infection (i.e. whether disease was 
invasive or not) was dropped from all of the multivariate models as there were no non-
invasive cases in the models. 
4.7.3 Microbiological factors 
In univariate logistic regression, the following microbiologic factors were significantly 
associated with each MDR pattern: 
 ESBL production: ESBL-producing isolates were more likely to have either or more 
than one of the MDR patterns. This was expected as ESBL-producing bacteria are 
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known to display resistance to other classes of antibiotics (Kruger et al, 2004 ; Turner, 
2005). 
 Resistance to TMP-SMX: Isolates that were resistant to TMP-SMX were also more 
likely to have at least one of the MDR patterns observed and this may be attributable 
to co-resistance (CDC, 2004). In particular the ACSSuT MDR pattern is also known to 
be resistant to TMP-SMX and floroquinolones (EMEA, 1999). Isolates that were 
resistant to TMP-SMX were more likely to have the ACSSuT, ACKSSuT or AKSSuT 
resistance patterns, these associations were independent of other explanatory factors 
included in the multivariate model.  
 Serotype: S. enterica Isangi isolates were more likely to have any one or more of the 
MDR patterns investigated. S. enterica Enteritidis isolates were less likely to have any 
one or more of the MDR patterns than S. enterica Typhimurium isolates. This is 
consistent with differences in resistance by NTS serotype reported previously (APUA, 
2003). 
In multivariate regression modeling of the odds of having either one or more of the four 
MDR patterns: 
 ESBL production remained significant in all the models.  
 TMP-SMX resistance was significantly associated with the ACSSuT, ACKSSuT and 
AKSSuT patterns, as well as with having more one or more MDR pattern.  
 Serotype remained significantly associated with the ACSSuT and ACSSuTNx MDR 
patterns, and with having at least one MDR pattern, contrary to what Kariuki et al 
observed in Kenya (Kariuki et al, 2005). 
4.8 Association between invasive disease and TMP-SMX resistance 
Invasive disease was associated with an 13% decrease in the odds of an isolate being 
resistant to TMP-SMX. This is contrary to what is expected from the literature, as invasive 
disease is known to be associated with resistance (CDC, 2004; Fisk et al, 2005; Rabatsky-
Ehr et al, 2004). 
4.9 Limitations of this study 
There was a large number of isolates (81.90%) for which patients’ prophylactic TMP-
SMX usage was not ascertained (either recorded as unknown or missing). This is primarily 
because this information would only be solicited by the enhanced surveillance sites, 
 67
effectively causing non-standardised data collection. Similarly, HIV status, antibiotic use 
in the two months preceding admission and immune compromise was not ascertained for a 
large proportion of patients who contributed isolates (see Section 3.2). The possibility that 
this has introduced bias has to be taken into account.  
The CLSI breakpoints were not specifically developed for Salmonella, and are therefore 
not ideal for determining antimicrobial susceptibility to this organism. 
It must be also be borne in mind that the database development and data collection 
processes were completed before the statistical analysis plan was written, certain questions 
could therefore not be adequately answered. 
A possible source of bias may have been the fact that there was no clear sampling strategy. 
This represents a limitation as the participants who make up the study sample may 
constitute people who have access to health care / are more likely to exhibit health-seeking 
behaviour, and because it is expected that provinces with academic centres may be more 
vigilant as regards disease surveillance. Furthermore, not all cases of salmonella are 
eventually detected and reported through surveillance (Alos et al, 2004) and so we cannot 
say with certainty how much the study sample represents the population. 
Furthermore, recall bias may be involved as some of the data gathered is reliant on 
participants’ / their relatives’ recollections of events post-diagnosis. 
As this study was based on cross-sectional data, it was not possible to demonstrate 
temporality or the direction of relationships. 
At the time of revising this report, a literature search was conducted to see if any updates 
on this subject had been published; nothing additional was found against which to 
compare the findings of this study. 
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5.0 CONCLUSIONS 
This study has identified high rates of resistance to 13 of the 15 antibiotics tested, with the 
highest resistance rates observed to sulfamethoxazole. 
We have also shown an association between TMP-SMX prophylaxis and two resistance 
patterns, viz. ACKSSuT and AKSSuT. Patients on TMP-SMX prophylaxis were 1.91 and 
2.00 times more likely to have NTS isolates with either the ACKSSuT or AKSSuT 
resistance patterns, respectively, than those who were not on TMP-SMX prophylaxis. 
Age, province of origin of isolate, prior treatment with antibiotics, site of infection, ESBL 
production, resistance to TMP-SMX and serotype were associated with all MDR patterns 
in univariate regression modeling. There did not seem to be any significant difference in 
the proportions of MDR cases and controls from male and female patients in bivariate 
analysis and univariate regression.  
Demographic factors (age and province) were not significantly associated with any of the 
MDR patterns in multivariate regression. ESBL production remained associated with all 
MDR patterns in multivariate regression, while age, prior antibiotic treatment, HIV status, 
serotype and TMP-SMX resistance remained associated with different combinations of the 
MDR patterns investigated. 
TMP-SMX usage for NTS salmonella does not seem to be appropriate in view of the high 
rates of resistance observed. Although 76.61% of patients on TMP-SMX prophylaxis were 
resistant to it, we must emphasize that TMP-SMX prophylaxis’ usefulness still lies in 
preventing and treating other bacterial infections (such as pneumonia).  
 69
6.0 RECOMMENDATIONS 
 Patients presenting with NTS and on TMP-SMX prophylaxis should continue with that 
regimen and other antibiotics should be considered for the NTS treatment (if clinically 
indicated). 
 Greater awareness is needed on treatment adherence and the importance of completing 
prescribed regimens to minimize resistance.  
 It is important to continue with surveillance (especially in settings where TMP-SMX 
prophylaxis is available) as it can be used to monitor whether resistance rates are 
increasing or decreasing and to which antibiotics. 
 Improved data collection and quality control procedures to fully ascertain the extent of 
missing data – i.e. have a response for each question on the CRF, even if that response 
is unknown, code it as such. 
 Double data entry and verification of surveillance data at the EDRU to minimize data 
entry errors. 
 Trend analysis after sufficient data (at least 6 years worth of data) is collected to look 
at trends over time. It may be useful to repeat this analysis every three years to 
continue monitoring trends in resistance. 
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8.0 APPENDICES 
Appendix A – Enhanced surveillance protocol 
 
Enhancement of Surveillance for Trimethoprim-Sulfamethoxazole Resistant Invasive 
Respiratory and Diarrhoeal Disease in South Africa 
Dr Anne von Gottberg, Ms Linda de Gouveia, Ms Avril Wasas, Dr Shabir Madhi, 
and Prof Keith Klugman and others 
Respiratory and Meningeal Pathogens Research Unit NHLS/MRC/WITS (RMPRU) 
National Health Laboratory Service (NHLS) / National Institute for Communicable 
Diseases (NICD) 
Dr Karen Keddy, Ms Arvinda Sooka 
Enteric Diseases Reference Unit (EDU) 
NHLS / NICD 
Dr Anne Schuchat 
National Center for Infectious Diseases (NCID) 
Centers for Disease Control and Prevention (CDC) 
Atlanta 
Clinical and laboratory collaborators identified at 10 centers in the Republic of South 
Africa: to be called “Enhanced Respiratory and Meningeal Pathogens Surveillance 
Group” 
Representatives from the Department of Health (DOH): Dr Lindiwe Makobalo, Ms P. 
Netshidzivhani and Dr Hans van Heerden 
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Introduction: 
 
Surveillance of disease in South Africa includes both clinical and laboratory notification. 
It is only with the establishment of a truly national network of laboratories under the 
umbrella of the National Health Laboratory Service (NHLS), together with the 
commitment to public health issues in the establishment of the National Institute for 
Communicable Disease (NICD), that the possibility of representative surveillance in our 
country has been made possible. 
 
At present passive laboratory surveillance has been recommenced over the last five years 
for the following bacterial organisms: Salmonella spp., Shigella spp., Vibrio cholerae, 
Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type b. 
Susceptibility of these isolates are also being monitored, in line with awareness of 
international trends of increasing antimicrobial resistance. The information gathered from 
this surveillance plays an important role in the control and prevention of these diseases in 
our population, and drug susceptibility data are extremely useful to clinical care providers. 
 
The human immunodeficiency virus (HIV/AIDS) has increased the incidence of some of 
these diseases significantly, specifically S. pneumoniae and Salmonella spp.; and reduces 
vaccine efficacy of others, especially, H. influenzae type b disease. Other changes affected 
by the HIV/AIDS epidemic, including antimicrobial susceptibility in the face of antibiotic 
prophylaxis, need to be monitored and evaluated in order for us to respond to the needs of 
our communities. 
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Project description: 
 Over an initial period of one year, from February 2003 to February 2004, national 
surveillance of Streptococcus pneumoniae, Haemophilus influenzae, Neisseria 
meningitidis and Salmonella spp. causing invasive disease in children and adults in 
South Africa and isolated from the bloodstream or cerebrospinal fluid is to be 
enhanced. These data will guide the continuation of such surveillance over a period of 
5 years. 
 Ten centers are to be identified in the country that will allow for the collection of a 
large number of episodes (see below for list of centers). 
 Data to be collected are age, sex, type of specimen, clinical presentation, HIV status if 
available, other underlying diseases, vaccination history, previous antibiotic use in the 
last month, regular attendance at a clinic/day-care center etc., therapy, and outcome 
(see attached data form) 
 To assist in capturing these data each center will have a surveillance officer employed 
for the duration of a year, trained in capturing data and the ethical issues attendant with 
this. 
 All above bacterial isolates associated with invasive disease will be appropriately 
stored and sent to the RMPRU and EDU for typing and susceptibility testing 
 To identify community-based organizations, services and clinics in each center that 
may offer prophylactic antibiotics, and by means of a questionnaire to assess protocols 
followed. This will assist in evaluation of differences in trends in the different centers. 
 If possible to define the population that each hospital/hospital complex serves and to 
determine incidence of the each of the abovementioned infections. 
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 Monthly review of cases identified at each center, completeness of data collected and 
confirmation of viable isolate for each episode at RMPRU and EDU; and to address 
any shortcomings highlighted by this review. 
 
Problems to overcome: 
 The present system of national surveillance for some infections is laboratory 
dependent and at present has no formal system of audit. 
 Isolates and information are being sent to the central laboratory and there is little 
feedback. Regional laboratories want more ownership with regard to both isolates and 
to clinical data being captured. 
 A national health laboratory system has only recently been established and a 
representative laboratory network within South Africa is only now being created. 
 Collaboration with the Department of Health is vital and this communication channel 
is still being optimized. 
 Private and public laboratories also have to acknowledge the combined role played in 
the diagnosis of diseases of public health importance. 
 HIV/AIDS is playing an important role in the changing epidemiology of disease in our 
population, and interventions introduced may change antimicrobial susceptibility 
patterns of bacteria commonly isolated. 
 
Objectives of this project: 
 To strengthen sentinel surveillance in respiratory and diarrhoeal diseases (specifically 
of the following organisms: Streptococcus pneumoniae, Haemophilus influenzae, 
Neisseria meningitidis and non-typhoidal Salmonella spp.) 
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 To monitor antimicrobial resistance in the above pathogens causing disease in children 
and adults, in particular as it pertains to the use of trimethoprim-sulfamethoxazole in 
the care and support of patients with HIV/AIDS 
 To document temporal changes of burden of disease due to HIV/AIDS 
 To facilitate monitoring the use of cotrimoxazole (trimethoprim-sulfamethoxazole) 
 To idenitfy cases of disease due to the above organisms occurring despite 
cotrimoxazole prophylaxis and the proportion due to resistance 
 
Potential secondary objectives: 
• To compare resistance and other characteristics of episodes of pneumococcal and 
Salmonella spp. invasive disease between hospitals in the enhanced surveillance 
and private hospitals reporting to RMPRU 
 
Strategies to achieve these objectives: 
 To improve substantially the data collected in 10 hospital/complexes in the country by 
placing increased resources in these centers: staff, training and on-site visits will be 
included 
 To evaluate some of the reasons for poor data and/or isolate collection 
 To improve the flow of information from hospital to regional laboratory to national 
surveillance laboratory to national government and back to the source laboratories and 
hospitals 
 
Results and benefits expected: 
 Improved national surveillance of the above bacteria by addressing issues identified 
during this project and by improved communications within the networks established 
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 Important influences of HIV/AIDS on the above diseases will be recognised and can 
be addressed 
 Using trends in these opportunistic infections to assess the HIV epidemic and its 
control 
 Effects of prophylactic use of trimethoprim-sulfamethoxazole can be quantified and 
may lead to changes in this intervention or better mechanisms to guard against its 
effects 
 
 
Plan and proposed time lines: 
 
1. Identify 10 hospitals/complexes for enhanced surveillance: in consultation with all 
relevant parties (November 2002). In each center both clinical and laboratory 
collaborators will be identified. 
2. Finalise data collection forms together with a clear data dictionary that 
explains/defines each variable and an instruction sheet to assist in the completion of 
the forms; forms will be piloted with users at different centres (January 2003) 
3. Ethics approval for prospective data capture that is not already contained in our 
surveillance ethics approval (reference number: 00105; granted 8/2/2000) has been 
granted in October 2002. Each site will need to assess ethics and/or procedural 
requirements. 
4. Hiring of 10 surveillance officers in the regions by the project collaborators identified 
in those regions (January and February 2003); hiring of 2 project co-ordinators 
(November/December 2002); hiring of 2 data clerks (November/December 2002) 
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5. Convene meeting of surveillance officers: education and preparation of surveillance 
officers with regard to principles and ethics of data capture; familiarization with 
surveillance procedures including data capture, transmission and audit (March 2002) 
6. Provide regular feedback to sentinel sites 
7. To commence piloting enhanced surveillance by end of March/April 2003. 
8. Follow-up (annual?) meetings (mid to late 2003) 
 
 
Methods: 
 
 Surveillance officers will review laboratory records to identify all blood and 
cerebrospinal fluid cultures that are positive for Salmonella spp., Streptococcus 
pneumoniae, Neisseria meningitidis and Haemophilus influenzae in adults and 
children. This will be done almost daily at centers with large numbers of positive 
cultures, and once or twice weekly at other centers. 
 Surveillance officers will oversee the completion of laboratory and clinical data on 
data capture forms (draft form attached). 
 All centers will require evaluation of the hospitals and populations drained by each 
laboratory (need to define population data in provinces vs cities vs urban centers) 
 Weekly planning of travelling between hospital/complexes as required to capture the 
relevant clinical information. 
 Isolates identified in the laboratory will be sent to RMPRU and EDU on an ongoing 
basis (within days of isolation) through the internal laboratory transport system. These 
will be processed immediately (serotyping, susceptibility testing) and results will be 
entered into the database (Regional Laboratory Data Form to accompany isolates). 
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 On a weekly/monthly basis completed clinical forms will be faxed or sent to the 
central laboratory and entered into a central database by data clerks (Clinical Report 
Form). Options for clinical data entry at sentinel complexes to be discussed, once 
surveillance officers are trained and facilities are available, this will be done at the 
regional level. 
 Study co-ordinators and surveillance officers will evaluate the database on a monthly 
basis and compare to monthly statistics generated from the DISA laboratory computer 
system. In addition they will summarize data for regular feedback 
 Study co-ordinators will at other times be travelling to each center to assist in setting 
up the networks required to complete the questionnaires, help the surveillance officers 
plan their schedule with regard to data collection, laboratory review 
 During these visits mini-audits for sensitivity of the surveillance system can be 
performed. 
 Exclude all duplicate entries as identified by name, laboratory of isolation, and date of 
specimen. 
 Repeat specimens from the same patient will be evaluated for type of organism and 
serotype/serogroup, as well as timing of second specimen e.g. same isolate within a 
period of 4 weeks, may be evaluated as persistent (2 to 7 days) versus recurrent 
 
 82
 
Possible hospitals/complexes: 
1. Umtata 
2. Bloemfontein Complex (initially 1 surveillance officer, workload will determine 
additional staff) 
3. Chris Hani Baragwanath Hospital 
4. Johannesburg General Hospital 
5. Medunsa 
6. Durban Complex (2 surveillance officers) 
7. Nelspruit 
8. Polokwane 
9. Mafikeng 
10. Cape Town Complex (2 surveillance officers) 
Evaluation: 
 Comparison of data collected in the same centers in the year preceding the project. 
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 Establish and track surveillance performance indicators (e.g. percentage of episodes 
with isolates tested; percent of cases reported within a threshold time period; percent 
of cases with data on HIV status and prophylaxis) 
 Evaluate the ease and sustainability of good quality ongoing surveillance in the future: 
questionnaires to laboratory and clinical staff to improve and facilitate sustainable data 
capture and submission of forms and isolates; this will be to ensure simplicity, 
acceptability and flexibility of any future surveillance. 
 Establish advisory committee with internal and external representation 
 Presentation of data to HIV/AIDS clinicians and discuss possible changes in hospital 
and clinic policies if required. 
 
Measures of Effectiveness: 
• Distribution of information gathered to key players involved. Initially at an annual 
meeting with all involved in the surveillance, this includes the DOH, to carefully 
assess conclusions drawn and recommendations made. Then to widen the 
distribution of information to clinicians and laboratories at other centers, the SA 
HIV Clinicians Society, and other parties to be identified. 
• Measures of effectiveness would include reviewing implementation of any changes 
recommended, acceptability and usefulness of data distributed as determined by 
the parties receiving the annual reports. 
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Appendix B – Case record form and informed consent 
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Title of project: Enhancement of Surveillance for Trimethoprim-Sulfamethoxazole 
Resistant Invasive Respiratory and Diarrhoeal Disease in South Africa 
Patient information sheet: 
Hello. My name is ___(name of surveillance officer or clinician at each centre)____and I 
would like to ask you for a little of your time to explain something to you, and ask you to 
please assist us in some work we are doing. As we discuss the information below please 
feel free to ask any questions. 
 
In South Africa and elsewhere in the world, hospital laboratories and the Department of 
Health look at specific diseases making people sick. By doing this so-called 
“surveillance”, we count how many people get sick and collect anonymous details about 
patients to help in the control and prevention of these diseases. Antibiotics/medicines can 
be used to prevent the diseases, so can vaccines, and when the number of cases increases 
the health community can be prepared. We are at present doing a study that will be 
looking at the use of certain antibiotics/medicines in the community and how it affects the 
germs that infect people. We want to see if there is an increase in germs that will not be 
treated by antibiotics/medicines that we normally use. 
 
As part of our surveillance we keep information about the infection that you have. We 
would like to make sure that all the information we have about you is correct and then ask 
a few more questions about use of antibiotics. We will keep this information confidential, 
no one else will know that it is about you and all summaries or publications will only refer 
to group data. We would also like to ask you to volunteer to have an HIV test done, but 
this will only be done once you have received full pre- and post-test counselling and are 
given all the details that you require to make a decision about taking a test. Even if you 
decide not to take the HIV test, we would still like to ask you a few questions, if you 
agree. 
 
You can make the decision entirely on you own and none of us can force you to take part. 
If you decide to answer some of these questions, you may also change your mind at any 
time. 
 
You do not have to agree, and if you decide not to be involved it will not change the way 
you are treated in the hospital, and your doctor will not do anything differently. 
 
Thank you for your time. Once you have asked any questions you may have, there is a 
form you need to sign if you agree to take part. 
 
Surveillance officer details. 
 
Details of clinician at centre. 
Title of project: Enhancement of Surveillance for Trimethoprim-Sulfamethoxazole 
Resistant Invasive Respiratory and Diarrhoeal Disease in South Africa 
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Patient assent form: 
 
Hello. My name is ___(name of surveillance officer or clinician at each centre)____and I 
would like to ask you something. I will need to explain what it is we would like to do. You 
can help us a little if you listen and tell us what you think. 
 
We want to ask you and your mother/father/caregiver some questions about you and the 
sickness you have. We will ask questions about when you were sick and about what 
medicines you took before you came to hospital. We want to try and see if these germs are 
causing more sickness in South Africa and if they are becoming more difficult to treat. 
 
Would it be alright for us to ask the above questions? When we work with this information 
we leave out your name. 
 
You must not worry if you do not want to answer any questions, nothing will change in 
how the doctor is taking care of you. 
 
Surveillance officer details. 
 
Details of clinician at centre. 
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Title of project: Enhancement of Surveillance for Trimethoprim-Sulfamethoxazole 
Resistant Invasive Respiratory and Diarrhoeal Disease in South Africa 
 
Informed consent form: 
 
I have read and/or I understand the contents of the information sheet and understand that I 
have been invited to participate, that my agreeing is fully voluntary, and that I can 
withdraw at any time. 
 
 
 
Consent given: 
 
 
Date: 
Witness: 
 
 
Date: 
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